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ABSTRACT
Clenbuterol is a commonly prescribed β2-adrenergic agonist approved for veterinary use as a
bronchodilator in horses with reactive and obstructive airway disease. Potential for abuse of this drug in
the horse industry is substantial, due to the perceptions that clenbuterol increases performance and lean
muscle mass. Although anabolic effects have been confirmed in multiple species, recent studies into the
effects of clenbuterol in exercising horses suggest that clenbuterol doses within therapeutic ranges
negatively impact aerobic capacity and cardiac function. Results of studies in murine models
demonstrate that clenbuterol directly induces skeletal and cardiac muscle cell death at high doses.
Three cases of equine clenbuterol overdose are described, in which clinical signs of toxicity
included tachycardia, muscle tremors, sweating and colic. Major laboratory abnormalities included
hyperglycemia, azotemia and elevated creatine kinase activity. Two horses were euthanized due to
complications of toxicity. Post-mortem abnormalities included skeletal and cardiac muscle necrosis.
The experimental study reported here examined the effects of oral clenbuterol on skeletal and
cardiac muscle in clinically healthy horses undergoing treadmill exercise, as compared with a control
group. Additionally, serum clenbuterol concentrations were measured throughout the treatment period.
This study was approved by the Louisiana State University Institutional Animal Care and Use
Committee. Twelve clinically healthy Thoroughbred horses between the ages of 3 and 10 years old were
randomly assigned to either the control group (n=6) or the clenbuterol group (n=6). Animals in the control
group received saline by mouth twice daily for 14 days. Horses in the clenbuterol group received
clenbuterol by mouth twice daily for 14 days, at incrementally increasing doses up to 3.2µg/kg. Horses
were subjected to daily submaximal treadmill exercise during the treatment period. Muscle biopsies were
collected before and after treatment for determination of apoptosis. Echocardiographic measurements,
serum clenbuterol concentration, and serum activities of creatine kinase, aspartate aminotransferase and
cardiac troponin I were measured before, during, and after treatment. Venous blood samples were
collected from the jugular vein(s) every 3 days during treatment. Echocardiography was repeated every 7
days after beginning treatment.
Serum biochemical and echocardiographic response variables were summarized as median and
range. These variables were compared between treatment groups and across time periods using a
x

Mann-Whitney U test and Friedman’s test for repeated nonparametric data, respectively. An adjusted
level of significance at p<0.01 was used to reduce type I error. The presence of apoptosis in muscle
biopsy samples was compared using a Cochran-Mantel-Haenszel stratified analysis, with a significance
level of p<0.05. Serum clenbuterol concentrations and percent apoptosis were summarized as mean ±
standard deviation.
No significant effect of clenbuterol or exercise on response variables was found between
treatment and control groups at any time point, nor within groups over time. Clenbuterol was detected in
the serum of all clenbuterol group horses during the treatment period. This study did not demonstrate
any adverse effects of a 2-week course of clenbuterol treatment on equine cardiac or skeletal muscle at
approved doses for treatment in horses.
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CHAPTER 1. INTRODUCTION
1.1 General Introduction
The use of performance-enhancing substances among human and equine athletes has long been
the subject of intense scrutiny and regulation. Clenbuterol is one such substance that enjoys a unique
place in sports medicine; despite its potential for abuse, it has been shown to be beneficial in the
treatment of equine recurrent airway obstruction (RAO) and inflammatory airway disease (IAD)1, and it
may slow the progression of disuse atrophy in humans2,3.
Clenbuterol is approved for use in non-food producing horses for treatment of respiratory disease
involving the small airways, when administered orally at 0.8µg/kg to 3.2µg/kg twice daily for up to 30
days. Beneficial effects pertinent to the treatment of small airway inflammation include bronchodilation of
small airways and enhancement of mucociliary clearance. Although clenbuterol is classified as a β2adrenergic agonist, its selectivity is only moderate, meaning that β1 and β3 receptors are also activated,
albeit at a lower frequency. Additionally, the distribution of β2 receptors in multiple organ systems results
in a wide range of effects on the body as a whole.
Initial safety studies required for USDA approval indicated that side effects in horses were
transient and relatively mild (NADA 140-793); however, numerous recent investigations have documented
negative effects of clenbuterol on athletic performance4-7. Results of studies in laboratory animals
suggest that the overall response of skeletal and cardiac muscle to clenbuterol may be partially mediated
through a dose-dependent induction of myocyte cell death8-12. Skeletal muscle appears to be more
susceptible to the myotoxic effects of clenbuterol9,12.
Because clenbuterol is routinely administered to performance horses for reasons other than
respiratory illness, and these horses are typically not under veterinary supervision for adverse side
effects, closer investigation into the potential risks of clenbuterol use among equine athletes not suffering
from restrictive airway conditions is warranted. No studies to date have specifically examined the effects
of therapeutic doses of clenbuterol on skeletal myocyte cell death in the horse or its relation to serum
clenbuterol concentration and common biochemical markers of muscle injury, such as creatine kinase
(CK) and aspartate aminotransferase (AST). Additionally, the duration of treatment required to produce
alterations in the echocardiogram is unknown.
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1.2 Hypotheses and Study Objectives
The purpose of the study reported here is to report 3 cases of clenbuterol toxicity in the horse,
and to determine if skeletal or cardiac muscle injury and/or cell death occurs in healthy, exercising horses
receiving clenbuterol at doses normally prescribed for treatment of respiratory disease. The mechanisms
by which clenbuterol may negatively affect aerobic performance appear to be multi-factorial and are not
well-elucidated. Potential mechanisms pertinent to this work are induction of myocyte necrosis and
remodeling of muscle tissue via initiation of apoptosis.
The first objective of this study is to report 3 cases of clenbuterol toxicity in the horse with
documented tissue and serum clenbuterol concentrations, and to report the occurrence of skeletal and
cardiac muscle injury in 2 of these horses.
The second objective is to determine if clenbuterol administration at normally prescribed doses is
associated with an increase in apoptosis or necrosis in equine skeletal muscle. The working hypothesis
is that the frequency of apoptosis will be significantly higher in horses administered clenbuterol for 14
days than in saline-treated controls.
The third objective is to determine if changes in cardiac function can be induced during a 14-day
treatment with clenbuterol. Working hypotheses are that changes in left ventricular measurements will be
present in all horses after exercise conditioning, and that measurements will be significantly different in
horses receiving clenbuterol, compared with controls.
The final objective is to determine if common biochemical markers of skeletal and cardiac muscle
injury are useful diagnostic tools for the detection of clenbuterol-induced skeletal or cardiac muscle injury.
The working hypotheses are that activities of CK, AST and cardiac troponin I (cTnI) will be significantly
higher in clenbuterol-treated versus control group horses, and that elevations in enzyme activities will be
associated with histologic, echocardiographic or clinical evidence of muscle injury.
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CHAPTER 2. LITERATURE REVIEW
2.1 Role of Clenbuterol in Veterinary Medicine
2.1.1 Therapeutic Use in the Horse
Clenbuterol has been licensed in the United States since 1998 for use in the treatment of lower
respiratory disease in horses (NADA 140-793), where bronchodilation and enhancement of mucociliary
clearance are desired effects. The two most common disease syndromes for which clenbuterol is
prescribed are recurrent airway obstruction (RAO) and inflammatory airway disease (IAD), although it
may be used as an adjunct treatment in cases of bronchopneumonia. RAO and IAD are both considered
syndromes of airway hyperreactivity, resulting in impairment of blood-gas exchange by excessive tracheal
and small airway mucus accumulation, neutrophilic airway inflammation and bronchoconstriction.
RAO typically affects an older population of horses and is seasonally progressive without careful
environmental management. Neutrophilic inflammation, increased airway secretions, bronchoconstriction
and thickening of the bronchiolar walls produce the classic clinical signs of increased respiratory rate,
increased respiratory effort, coughing and exercise intolerance. Despite periods of remission, airway
remodeling further contributes to respiratory compromise over time, including respiratory epithelial
metaplasia, peribronchiolar infiltrate and bronchiectasis. Acute episodes of RAO may be reliably
triggered by exposure to hay molds or pasture antigens, and significant elevations in normal intrapleural
pressure changes accompany clinical signs of RAO, as opposed to horses afflicted with IAD13. Forty-two
to seventy-five percent of horses affected with RAO that responded to atropine challenge also responded
to clenbuterol, based on either remission of clinical signs or reduction in intrapleural pressure change
(NADA 140-973). Because of the progressive nature of RAO, long-term or repeated therapy with
bronchodilators is often required to manage symptoms, especially during respiratory crises.
Conversely, IAD is a disease of younger horses in which pleural pressure changes and airway
remodeling are not observed. The disease is commonly diagnosed in performance horses and may
result from post-infective airway hypersensitivity associated with outbreaks of viral and bacterial
respiratory disease in large training facilities14. Estimates of prevalence in performance horses range
from 14% in young British racehorses15, up to 70% in poorly-performing National Hunt horses16 and 74%
among Japanese racehorses evaluated for poor performance17. The disease often reduces performance
3

and is characterized by alterations in tracheal mucus quantity, which have been scored from 0 to 5 using
the tracheal mucus scoring system in Figure 118. Mucus scores of 2 or greater are associated with poor
racing performance19. Tracheal secretions contain increased numbers of neutrophils, and mast cells are
frequently present13, although total inflammatory cell counts are lower than those of horses affected with
RAO.

Figure 1. Scoring system for tracheal mucus, based on endoscopic observation.
2.1.2 Potential for Abuse
Clenbuterol abuse has been reported in humans and most livestock species, where it is used to
increase lean muscle mass. Use in livestock was prohibited after multiple cases of human toxicosis
resulted from ingestion of clenbuterol residues in muscle and liver20-23. In horses, clenbuterol is used
outside a valid veterinary-client-patient relationship due to an industry perception that it is a non-specific
performance-enhancing drug. In addition, clenbuterol has been advocated for the treatment of other
performance-limiting respiratory conditions, most notably exercise-induced pulmonary hemorrhage
(EIPH). Objective evaluation of its value in prevention of EIPH failed to demonstrate any benefit24.
2.1.3 Regulation of Clenbuterol in the Horse Industry
Clenbuterol is tightly regulated in the US flat racing industry, and specific withdrawal times for the
drug prior to racing are established by each racing commission. Detection of the drug above allowable
concentrations in the urine or blood post-race can result in disciplinary action against the horse’s trainer
or owner. English performance horses participating in FEI and USEF-sanctioned events are strictly
prohibited from receiving clenbuterol; the animal must be withdrawn from competition even if the drug
was given under a veterinarian’s direction. However, client access to large quantities of clenbuterol is
perpetuated because of the relatively high frequency of IAD in the performance horse population, for
which clenbuterol is a popular treatment. Additionally, use of clenbuterol is not regulated in many
4

disciplines, nor is it uniformly regulated at all levels of competition. These situations further engender
questionable use of clenbuterol within the horse industry, i.e. administration outside of a valid veterinaryclient-patient relationship.
2.2 Pharmacology
2.2.1 Pharmacokinetics and Tissue Distribution
Clenbuterol is rapidly absorbed in less than 15 minutes following oral administration with a
bioavailability of 83%25. With twice daily administration of 1.6µg/kg clenbuterol by mouth, half-life was
calculated to be 12.9 hours, and mean steady-state serum concentrations of 508.1pg/ml were achieved
after 48 hours25. Clenbuterol is metabolized in the liver and is primarily excreted in the urine, with a small
percentage (<5%) excreted in the feces. Urine concentrations are 100 times greater than plasma
concentrations, and clenbuterol may be detectable in the urine for up to 12 days25. Prolonged urinary
excretion may be due in part to clenbuterol distribution in the tissues; tissue clearance (elimination halflife is >21 hours for all tissues) is prolonged relative to serum clearance26. The liver, lung and left ventricle
contain the highest concentrations of clenbuterol. Following 2 weeks of clenbuterol administration,
tissue/plasma ratios of clenbuterol concentration in the liver (42.2), eye fluids (21.5), lung (9.9) and left
ventricle (7.2) were significantly elevated 72 hours after administration of the final dose26. Clearance from
the pectoralis muscle was fastest of all tissues sampled in this study.
2.2.2 Distribution of β-Adrenoreceptors in the Horse
The multi-systemic effects of clenbuterol are mediated by the distribution of β-adrenoreceptors in
the body. It is considered a moderately selective β2-adrenergic agonist with dose-dependent effects on
multiple organ systems. β2 adrenergic receptors are present in skeletal and cardiac myocytes,
hepatocytes, sweat glands, nervous tissue, respiratory smooth muscle, vascular smooth muscle, uterus,
and ileum1,12,27-30. β1 adrenoreceptors are present in the heart and may be activated directly with high
doses of clenbuterol, or secondarily via release of norepinephrine from β2-stimulated sympathetic
neurons. Clenbuterol is also reported to activate β3 (or “β-atypical”) receptors, which are purportedly
responsible for the lipolytic and other repartitioning metabolic effects of clenbuterol, and which are
relatively insensitive to blockade by the majority of β-adrenergic antagonists, including propranolol1,27.
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2.2.3 Effects at the Cellular and Molecular Level
β2 adrenoreceptors are coupled to G proteins that mediate a vast array of second-messenger
signaling pathways31. In the uterus, ileum, vascular smooth muscle and respiratory smooth muscle, β2
receptors generally mediate smooth muscle relaxation through adenylyl cyclase-mediated inhibition of
acetylcholine release. In the liver, gluconeogenesis is induced.
Norepinephrine is released from post-synaptic sympathetic cardiac neurons in response to β2
activation28. Positive inotropic and chronotropic effects on the cardiac muscle are mostly mediated by the
action of norepinephrine on cardiac β1 receptors. However, β2 adrenoreceptors comprise approximately
30% of the receptor population of the atrial myocardium and 18% of the ventricular myocardial receptors
in the horse32. At sufficiently high doses, cardiac β1 receptors may also be activated directly by
clenbuterol.
In skeletal muscle, β2 stimulation results in alterations of intracellular calcium content33, which
may result in either increased contractile force or cell death. Clenbuterol has been studied extensively in
human medicine as a potential therapeutic agent for diseases of muscle wasting, such as disuse atrophy,
cachexia or decreased cardiac load in left ventricular assist device support3,34-36. Recent research has
indicated that clenbuterol may inhibit protein degradation in skeletal muscle by G protein-mediated
inhibition of calpain activation and ATP-dependent ubiquitination35. Clenbuterol may also modulate the
ubiquinin-proteasome pathway by a mechanism unrelated to β-adrenoreceptor activation2. Specific
effects of β2 stimulation on skeletal and cardiac muscle are discussed further in the sections to follow.
2.3 Adverse Effects and Toxicity
2.3.1 Clinical Signs of Toxicity
Toxic effects of clenbuterol may be generally considered to be caused by excessive sympathetic
stimulation. During safety trials in horses, the most common side effects were sweating (27.6%), muscle
tremors (18%) and anxiety (2.8%). Signs were more profound at higher doses, but all resolved without
intervention in a few hours. Reported cases of clenbuterol toxicity in humans describe sinus tachycardia,
myalgia, gastrointestinal upset, and hypokalemia as the most common clinical signs20-23,37-39.
Supraventricular arrhythmias have also been reported in association with clenbuterol ingestion in
people40. The recommended treatment of clenbuterol toxicity in humans is administration of a β6

adrenergic antagonist (i.e., propranolol or esmolol) and correction of glucose and electrolyte
abnormalities37,38,40,41. Repeated administration of β-adrenergic antagonists is frequently required37,38, as
toxic effects can last up to 6 days39.
2.3.2 Species Variation in Toxicity
Mice and other livestock species appear to tolerate significantly higher doses of clenbuterol than
horses with no demonstrable side effects. Doses reported to induce “repartitioning” in cattle are as high
as 30µg/kg1. In numerous murine experiments, clenbuterol was administered at doses from 10µg/kg up
to 2mg/kg/day in both brief, terminal experiments and long-term exercise physiology studies4,8-10,33,42,43.
Interestingly, although muscle injury was documented in rats receiving clenbuterol12, no clinical signs of
toxicity were described in any murine study. In contrast, equine and human reports of toxicity are
numerous. In Chapter 3, sustained tachycardia, muscle tremors, and skeletal and cardiomyocyte
necrosis were described in a horse that received an estimated dose of 10µg/kg clenbuterol. Similarly,
reported cases of human toxicity describe the occurrence of toxicosis with ingestion of clenbuterol doses
between 0.9µg/kg20 and 4.8mg/kg37. This apparent discrepancy may be explained as failure to recognize
these clinical signs in rodents; alternatively, it may suggest that there is a wide species variation in
sensitivity to clenbuterol, with horses being exquisitely sensitive to β-adrenergic stimulation.
2.4 General Effects on Performance
Although the primary reason for clenbuterol abuse is, generically speaking, performance
enhancement, results of investigation into objective measures of performance enhancement are mixed.
Multiple studies agree that clenbuterol enhances lean muscle mass3,10,33,42,44-46, but whether this
translates into increased muscular strength is controversial. Conversely, a majority of investigations also
suggest that clenbuterol has a negative effect on endurance and exercise tolerance4-7. Decreased
performance on a standardized exercise test was observed in Standardbred mares receiving 2.4µg/kg
clenbuterol for 8 weeks5. When treadmill velocity was measured as a function of heart rate, Arabian
horses administered a single 0.8µg/kg intravenous dose of clenbuterol 30 minutes prior to treadmill
exercise were unable to achieve comparable speeds to control horses7. An increased incidence of
sudden death from cardiac failure was also observed in one study of exercising rats receiving
clenbuterol4. The specific mechanism(s) by which clenbuterol exerts these effects are still unclear.
7

2.5 Effects on the Musculoskeletal System
2.5.1 Increase in Lean Muscle Mass
Clenbuterol causes an increase in lean muscle mass in all mammalian species studied. This
effect is one of the primary reasons for its abuse in human body-builders and food-producing animals. It
is partly mediated through a relative loss of fat mass in conjunction with muscular hypertrophy, a
phenomenon known as repartitioning. Clenbuterol may promote lipolysis through its action on β3
receptors in adipose tissue. Additionally, increased serum concentrations of adiponectin and decreased
concentrations of leptin have been reported in horses receiving clenbuterol47. In another study of
Standardbred mares receiving 2.4µg/kg clenbuterol for 8 weeks, total body weight increased by
approximately 4%, while ultrasonography was used to demonstrate a decrease in rump fat thickness44.
Interestingly, in this same study, exercise appeared to attenuate the gain in muscle mass (fat free mass)
in horses administered clenbuterol, as opposed to horses receiving clenbuterol alone. In rats,
administration of clenbuterol reliably increases skeletal and cardiac muscle mass by 11-29%4,10.
Although an increase in the collagen weight (fibrosis) of skeletal and cardiac muscle may also contribute
to the overall increase in muscle weight4,10, true cellular hypertrophy also occurs10,42.
2.5.2 Effects on Skeletal Muscle Strength
Tensile strength in skeletal muscle can be measured and expressed in various ways; the
methodology of choice often determines whether an effect of clenbuterol will be reported. Generally, if
muscle groups are considered as a whole, an increase in strength is noted. In one study of human
volunteers, there was a trend towards higher maximal voluntary strength in subjects receiving clenbuterol
versus placebo3. This effect is likely due to increased muscle mass or hypertrophy, as it is seldom
reported when peak force is adjusted for muscle weight or cross-sectional area. In rats receiving
2mg/kg/day clenbuterol for 2 weeks, an increase in overall leg muscle force was demonstrated using
electrostimulation; however, no effect was seen when data were adjusted for the increase in muscle
mass42. Conversely, long-term clenbuterol administration in horses did result in generation of increased
force per cross-sectional area in the gluteus medius muscle48.
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2.5.3 Alteration of Skeletal Muscle Fiber Composition
Some of the physiologic effects of clenbuterol may be due to a shift in myosin heavy chain
composition of skeletal muscle. Myosin heavy chains are categorized as type I, type IIA and type IIX.
Clenbuterol induces a shift towards type II (specifically type IIX) myosin heavy chain fibers, which
normally predominate in “fast-twitch” muscles42,45. This effect is most pronounced in “slow-twitch”
muscles such as the soleus, in which type I heavy chains constitute the majority of fibers, and where the
greatest concentration of β-adrenoreceptors is present49. In rats, these muscles undergo the most
changes in dry weight, tensile strength and percentage of cell death in response to clenbuterol
administration2,8,10,42,43. This effect may be due in part to the failure of slow-twitch muscles to undergo β2
receptor tachyphylaxis, as occurs in fast-twitch and cardiac muscle50.
Since aerobic conditioning through exercise produces a shift in muscle fiber composition from
type IIX to type IIA or type I fibers, Beekley et al proposed that the clenbuterol-induced fiber composition
shift towards type IIX directly reduces aerobic capacity45. Others have attributed decreased aerobic
capacity to suppression of intracellular phosphofructokinase activity associated with clenbuterol
administration42.
2.5.4 Modulation of Skeletal Muscle Cell Death
A differential effect of clenbuterol dose on the type of skeletal muscle change has been quantified
in the rat. Briefly, low doses induce muscular hypertrophy, and moderate-to-high doses (≥10µg/kg) result
in skeletal muscle apoptosis and necrosis8. The highest frequency of apoptosis (5.8%) was observed in
the soleus muscle 4 hours post-clenbuterol administration8, and necrosis (4.4%12 to 7.4%8) was most
severe in the soleus 12-15 hours after a single administration. No effect was observed in the anterior
tibialis muscle12, which is a fast-twitch muscle.
When clenbuterol was administerered to rats once a day for 14 days, higher doses
(≥100µg/kg/day) were required to induce detectable myocyte apoptosis, and the frequency of apoptotic
cells (0.15% to 0.3%) was lower than previously reported10. The apparent decrease in myotoxicity over
time may be due to β receptor downregulation. Administration of 10µg/kg clenbuterol every other day
failed to induce myocyte apoptosis after 8 days; however significant necrosis occurred for up to 16 days8.
Cell death is likely induced via signaling pathways downstream of the β2 receptor, as myotoxicity can be
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prevented in skeletal muscle by pre-treatment with β2-specific adrenergic antagonists, but not with β1adrenergic antagonists or norepinephrine depletion12,28.
Conversely, clenbuterol has been investigated in human medicine for its ability to slow the
progression of disuse atrophy2,35,43. This effect has not been uniformly reproducible in all models. The
implications of these findings for horses with pre-existing myopathies remain uncertain.
2.6 Effects on the Cardiovascular System
2.6.1 Changes in Hemodynamics
Clenbuterol lowers blood pressure by causing β2-mediated relaxation of vascular smooth muscle,
thereby decreasing systemic vascular resistance11. After the initial vasodilation, however, blood pressure
may be restored to normal via reflex increases in heart rate and pulmonary arterial pressure1. Changes in
ejection fraction have also been documented36, but these changes are primarily due to alterations in the
function of the myocardium itself, specifically prolonged ventricular relaxation time resulting in increased
left ventricular volume during diastole11. A 10% decrease in plasma volume has also been documented
in horses receiving clenbuterol5, although the mechanism for this phenomenon is unknown.
2.6.2 Changes in Cardiac Dimensions
Left ventricular hypertrophy is the most consistently reported effect of clenbuterol in humans and
laboratory animals4,6,34,35, and increased mural thickness may be due to a combination of true
hypertrophy34 and myocardial fibrosis4. The dose of clenbuterol administered may play some role in the
magnitude of changes detected; in 2 human trials with patients in cardiac failure, no echocardiographic
changes were reported using a total clenbuterol dose of 80µg/day (approximately 0.5µg/kg q 12 h) for 12
weeks3, but an increase in end-diastolic left ventricular volume occurred when patients were administered
clenbuterol at 720µg/day (approximately 3µg/kg q 8 h) for 12 weeks34. In horses receiving clenbuterol at
2.4µg/kg twice daily for 8 weeks, no echocardiographic alterations were evident at rest, but all parameters
measured were significantly different in treated horses following strenuous exercise, except for enddiastolic thickness of the left ventricular free wall6.
2.6.3 Changes in Cardiac Function
Besides inducing tachycardia, clenbuterol is also a positive inotrope and lusitrope. In rats, the
prolonged diastolic relaxation induced by fenoterol (another β agonist) results in an increased left
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ventricular filling pressure, which in turn reduces coronary blood flow and decreases cardiac output11.
Conversely, post-exercise echocardiography in horses receiving clenbuterol documented an increase in
stroke volume and cardiac output, as compared to control animals. However, the horses in this and other
equine studies also demonstrated increased right ventricular pressures and impaired cardiac recovery
post-exercise5,6. The conflicting conclusions regarding cardiac output may have been due to different
measurement techniques.
The arrhythmogenic potential of clenbuterol has been documented in at least one human case of
clenbuterol toxicity40. Proposed mechanisms for the increased risk of cardiac arrhythmia concentrate on
dysregulation of intracellular calcium35. Both an increase in myofilament sensitivity to ionized calcium36,
and an increase in the calcium content of the sarcoplasmic reticulum have been documented in animals
administered clenbuterol, with prolongation of the action potential as a result33. Additionally, decreased
taurine levels in cardiac tissue associated with clenbuterol administration may further destabilize cell
membranes and contribute to intracellular calcium leakage51.
2.6.4 Modulation of Cardiac Muscle Cell Death
Similar to skeletal muscle, cardiomyocytes appear to exhibit a dose-dependent response to
clenbuterol exposure. In the rat, apoptosis is first detected at clenbuterol doses of 1µg/kg9, and necrosis
occurs at doses ≥ 100µg/kg12. Additionally, the primary site of clenbuterol-induced cardiac injury appears
to be localized to a specific site near the apex of the left ventricle. The primary hypothesis behind this
occurrence is that of relative cardiac hypoxia during exercise; as previously described, the reduction in
coronary blood flow is greatest at this site. At this location, the maximum frequency of apoptosis was
reported to be 0.3%9, and the maximum frequency of necrosis detected was 0.87-1.0%8,12. In cardiac
muscle, stimulation of β1 receptors may also contribute to cardiotoxicity, as both β1 and β2-adrenoreceptor
inhibition, as well as norepinephrine depletion, significantly reduced the myotoxic potential of clenbuterol
in cardiac muscle9,28. Cardiotoxicity has been observed in humans40 and horses at doses well below
these levels.
Cardiac hypertrophy is reliably produced by clenbuterol administration; however some
investigations found that a part of the increase in cardiac mass may be due to an increase in collagen
mass, suggesting that fibrosis was due to irreversible induction of myocardial cell death. In one study,
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clenbuterol induced a 12-15% increase in cardiac protein content, and a 3% increase in cardiac collagen
content versus controls10. Further implications of these findings were discussed in the previous sections.
2.7 Ante-Mortem Evaluation of Myopathy in the Horse
Several diagnostic modalities are available to the equine practitioner for detection of myopathy.
Sufficiently severe myopathy of the skeletal musculature may result in widespread muscle necrosis or
rhabdomyolysis, which is characterized by stiff and painful musculature and release of myoglobin.
Common myopathies in Thoroughbreds and Quarter Horses include polysaccharide storage myopathy
(PSSM) and recurrent exertional rhabdomyolysis (RER), both of which can contribute to poor
performance and predispose the horse to clinical episodes of rhabdomyolysis. Cardiac dysfunction may
also contribute to poor performance. Methods of evaluation for skeletal muscle injury and
cardiomyopathy are outlined below.
2.7.1 Serum Biochemical Markers
The most commonly used biochemical markers for evaluation of skeletal muscle injury in the
horse are creatine kinase (CK) and aspartate aminotransferase (AST). Both are leakage enzymes that
are released into circulation only when there is significant loss of cell membrane integrity, thereby making
them useful in the diagnosis of muscle necrosis. Serum activity of CK peaks 4-6 hours following muscle
injury. Due to its short half life, CK activity declines to normal levels within 24 hours in the absence of
further muscle damage. Total CK activity is composed of 3 isoenzymes, CK-MM, CK-MB and CK-BB,
which originate primarily from the skeletal muscle, cardiac muscle and brain, respectively. The skeletal
muscle isoform contributes the majority of CK activity in the body; however, CK-MB constitutes 40% of
cardiac CK activity and is not expressed in any other tissue.
By contrast, AST activity peaks 6-10 hours after muscle injury. The half-life of AST is 18 hours in
the horse; therefore serum activity may take 4 or more days to return to normal levels. AST is also
released from hepatocytes and osteocytes, and increases in AST enzyme activity must be interpreted
carefully in light of CK activity and other organ function. Elevations in CK and AST activity in horses at
rest suggest the presence of clinically significant myopathy. Post-exercise elevations in CK activity have
also been used to support a diagnosis of subclinical myopathy in the evaluation of poor athletic
performance; reported criteria include a three-to-four-fold elevation in CK activity 4 hours after
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submaximal exercise52, or an increase in CK activity >1000U/L measured 30 minutes after a standardized
exercise test53.
Cardiac troponin I (cTnI) is an alternative marker of myocardial injury that, similarly to CK, is also
released from cardiac muscle during necrosis. Reference intervals (0-0.14ng/ml) have been established
in diverse populations of healthy horses, including horses used for flat racing54-56. Significant elevations in
cTnI activity in horses have been reported in cases of monensin cardiotoxicity57, valvular rupture58,
clinically significant arrhythmias58,59, piroplasmosis60 and other causes of myocarditis61,62. Measurement
of cardiac troponin is considered highly reliable in human medicine for diagnosis of myocardial injury63,
and clinical utility has also been documented in dogs64 for diagnosis and monitoring of cardiomyopathy.
Elevated cTnI was reported in one human case of clenbuterol overdose40.
2.7.2 Histopathology
Histologic evaluation of a semimembranosus/semitendinosus muscle biopsy is the recommended
procedure for identification of most myopathies that affect performance horses. Over 70% of Quarter
Horses with a histologic diagnosis of PSSM carry a mutation on the GYS1 gene encoding for glycogen
synthase65. This mutation has not been identified in Thoroughbreds affected with PSSM; therefore
histologic examination remains the only available tool for diagnosis of this condition in Thoroughbreds.
Detection of abnormal, amylase-resistant polysaccharide accumulation with periodic acid-Schiff stain is
the hallmark feature of PSSM in a biopsy section66. Other myopathies may be identified by alterations in
cellular morphology, such as loss of striations, atrophy, vacuolization or position of the nuclei within a cell,
or by the presence of inflammatory cell infiltrate and/or fibrosis.
The mechanism of myocyte cell death may also be determined using immunohistochemical
methods. In the mouse, Burniston et al describe the identification of skeletal and cardiac muscle necrosis
using a staining technique for localization of anti-myosin antibody8,12. Briefly, anti-myosin antibody was
administered intraperitoneally prior to induction of muscle injury, such that the anti-myosin antibody would
bind to any myosin exposed during necrosis. This method does not translate well to use in a large animal
such as the horse.
Apoptosis, or programmed cell death, is characterized histologically by irregular, pyknotic nuclei.
It may be triggered through a multitude of enzymatic pathways, most (but not all) of which involve
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activation of caspase 3. Another immunohistochemical target of apoptosis is the characteristic pattern of
DNA digestion which produces multiple DNA fragments of a characteristic length, all possessing free 3’OH termini. Common methods of identifying apoptosis in skeletal muscle in situ therefore rely on staining
for caspase 3 or the 3’-OH DNA terminus. Both caspase 3 antibody and terminal deoxynucleotidyl
transferase dUTP nick end labeling have been used successfully to demonstrate apoptosis in murine
skeletal and cardiac muscle8-10,12, and they have also shown utility in identification of apoptotic cells in
equine laminae67 and intestine68.
2.7.3 Echocardiography
Echocardiography permits direct sonographic visualization of the heart, allowing for the
identification of physical abnormalities such as septal defects or transposition of the great vessels,
valvular insufficiency or endocarditis, pericardial effusion or thickening, chamber enlargement, and
alterations in contractility. Myocarditis may be difficult to appreciate sonographically unless marked
fibrosis is present. Reference intervals for most echocardiographic measurements have been established
for adult Thoroughbred horses69,70. A post-exercise echocardiogram is defined as a study performed
during recovery from intense exercise, when the horse’s heart rate exceeds 100 beats per minute53.
Among Standardbred mares administered clenbuterol for 8 weeks, significant alterations in the postexercise echocardiogram included increases in aortic root diameter, systolic thickness of the left
ventricular free wall, thickness of the interventricular septum and left ventricular internal dimension6.
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CHAPTER 3. CLENBUTEROL TOXICITY IN 3 HORSES
3.1 Case Descriptions
3.1.1 Horse 1
A 482 kg (1060 lb), 7-year-old Quarter Horse stallion (horse 1) from a racetrack in southern
Louisiana was referred to the Veterinary Teaching Hospital & Clinics at Louisiana State University (LSUVTH & C) with a 16-hour history of muscle fasciculation, hyperhidrosis, colic and stiff gait. Clinical signs
occurred following oral administration of a compounded clenbuterol solution that was purported to contain
75µg/ml clenbuterol. The horse had been receiving clenbuterol as Ventipulmin® syrup (0.8µg/kg
[0.36µg/lb] PO) once daily; however this was the first time the compounded product had been
administered. Prior to referral, clinical signs had not responded to treatment with flunixin meglumine
(1.1mg/kg [0.5mg/lb], IV, once), acepromazine and oral electrolyte solutions.
At presentation, muscle fasciculations were present over the entire body. The right gluteal and
quadriceps muscles were firm and the horse was unwilling to bear full weight on the right hind limb.
Lameness was not altered by perineural anesthesia of the right hind digital nerves at the level of the distal
sesamoids. The horse was sweating, heart rate was increased (96 bpm) and capillary refill time was
prolonged (5 seconds).

Dehydration was estimated at 8% based on skin turgor. Nasogastric intubation

recovered 7 L net reflux; however, rectal examination was unremarkable. Abdominal ultrasound revealed
decreased corticomedullary definition and dilation of the renal pelvis in the right kidney.
Complete blood count showed hemoconcentration, leukocytosis and thrombocytopenia.
Biochemical panel showed increased activities of CK and AST, azotemia, hyperbilirubinemia,
hyperphosphatemia, hyperglycemia, hyponatremia and hypochloremia. Major clinicopathologic
derangements at admission are summarized in Table 1. Urinalysis revealed isosthenuria, aciduria,
glucosuria and a large amount of blood.
Emergency therapy consisted of methocarbamola (12 mg/kg [5.45 mg/lb], IV, once), rapid infusion
of intravenous crystalloid fluidsb, insulinc (0.25U/kg [0.11U/lb], IM, once); unfractionated heparind (40U/kg
[20U/lb], SQ, q 8 h) and butorphanole (0.04mg/kg, IV, once). Following the initial infusion, intravenous
fluid therapy was continued at 2L/h with a balanced electrolyte solution supplemented with calcium
borogluconate, potassium chloride and dimethyl sulfoxide. Despite transient improvement, the horse
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became increasingly agitated and uncomfortable. Phenylbutazonef (4.4mg/kg [2mg/lb], IV, once),
xylazineg (0.3mg/kg [0.15mg/lb], IV, once) and butorphanol (0.01mg/kg [0.005mg/lb], IV, once) failed to
relieve signs of pain.
Table 1. Major laboratory abnormalities approximately 24 hours after clenbuterol overdose.

Hematocrit (%)
TP (g/dl)
Glucose (mg/dl)
BUN (mg/dl)
Creatinine (mg/dl)
CK (U/L)
AST (U/L)
ALP (U/L)
Ca (mg/dl)
Na (mmol/L)
K (mmol/L)
Cl (mmol/L)
PT (sec)
PTT (sec)
Band neutrophils (x103/µl)
Platelets (x103/µl)

Horse 1
59.9
8.8
484
32
5.7
101,400
**
331
11.9
124
3.4
77
13.2
60.6
400
92

Horse 2
33.8
6.1
461
31
3.5
6,970
**
357
9.4
135
2.8
93
12.2
43.9
0
195

Horse 3
41.5
6.1
483
42
4.8
5,070
927
614
10.1
120
3.0
81
12.6
44.9
1,000
118

Reference Interval
32-52
6.1-8.1
70-105
12-26
1.2-2.0
0-350
0-350
0-250
11.3-13.4
130-140
3.0-5.0
97-105
8-10
32-42
100-600

** Not reported due to analyzer interference
Within 8 hours of admission, the horse became recumbent. Gluteal, quadriceps, and epaxial
muscle groups were firm bilaterally, and whole body muscle tremors continued. Tachycardia (112 bpm)
persisted, and a grade 3/6 end systolic heart murmur developed. Sinus tachycardia was confirmed with
electrocardiography. Reevaluation of the serum biochemical panel revealed persistence of all previously
described abnormalities except hyperglycemia and hyperphosphatemia. The leukogram on day 2 of
hospitalization revealed development of a left shift.
Fluid therapy was amended to include endoserumh (500ml, IV, 0.5L/h) and hetastarchi in addition
to crystalloid fluids. Intravenous calcium supplementation was also discontinued, and 7% sodium
chloride (10ml/L) was added to the balanced electrolyte solution. Heparin therapy was discontinued, and
naloxonej (0.016mg/kg [0.008mg/lb], IV, once), acepromazinek (0.06mg/kg [0.03mg/lb], IM, q 6 h),
furosemide (0.5mg/kg [0.25lb], IV, once) and dexamethasonel (0.04mg/kg [0.02mg/lb], IV, once) were
administered.
Analgesia was attempted with butorphanol (0.9mg/kg [0.4mg/lb], IM, once), xylazine (0.44mg/kg
[0.2mg/lb], IV, once), detomidinem (0.2mg/kg [0.1mg/lb], IV, once), guaifenesinn (11.1mg/kg [5.0mg/lb], IV,
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once). Constant rate infusion of butorphanol (0.013mg/kg/hr [0.006mg/lb/hr], IV) with periodic
administration of diazepamo (0.1-0.2mg/kg [0.05-0.1mg/lb], IV, PRN) and detomidine provided adequate
sedation to prevent self-mutilation. Additional supportive care included urinary catheterization, heavy
bedding, manual repositioning, eye lubrication, and placement of protective headgear and lower limb
bandages.
By the evening of day 2, the horse’s condition had further deteriorated. Neurologic abnormalities
included loss of coordinated motor activity in the rear limbs, absent menace responses, sluggish direct
pupillary light reflexes, and development of nystagmus after repositioning. Tachycardia and sweating
persisted, and body temperature decreased to 94.6°F (34.8°C). Disseminated intravascular coagulopathy
was suspected based on thrombocytopenia and prolonged prothrombin (PT, 13.2 sec [8-10 sec]) and
partial thromboplastin times (PTT, 60.6 sec [32-42 sec]). Azotemia and electrolyte derangements had not
resolved despite aggressive fluid therapy.
The compounded product believed to have caused this patient’s clinical signs was confirmed as
pure clenbuterol by electrospray-tandem mass spectrometry. The concentration of clenbuterol in this
product was determined to be 5.0mg/ml, which is approximately 70 times the concentration of the
licensed product. Clenbuterol was also detected in the horse’s serum at 5,450 pg/ml. Propranololp
(0.01mg/kg [0.005mg/lb]) was subsequently administered in 150ml physiologic saline solution as an
intravenous infusion over 30 minutes. Following propranolol administration, heart rate slowed from 90 to
60 bpm, and the systolic heart murmur became less pronounced. Sweating and anxiety were subjectively
decreased, but no effect on muscle stiffness was observed.
Dexamethasone (0.04mg/kg [0.02mg/lb], IV, once) administration was repeated, and
omeprazoleq (0.5mg/kg [0.23mg/lb], IV, q 24 h) and ceftiofurr (2.2mg/kg [1.0mg/lb], IM, q 12 h) were
administered. Transdermal fentanyl patchess (0.67µg/kg/h [0.3µg/lb/h]) were applied. Diuresis with
balanced polyionic solutions supplemented with magnesium sulfate (0.5g/L), potassium chloride
(20mEq/L), and 7% sodium chloride (10ml/L) was maintained at a rate of 2L/h.
On day 3 of hospitalization, reevaluation of neurologic, renal and musculoskeletal abnormalities
revealed further deterioration. The owners elected euthanasia, and the horse was euthanized by
barbiturate overdose approximately 50 hours after clenbuterol ingestion.
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3.1.2 Horse 2
A 516 kg (1135 lb), 2-year-old racing Quarter Horse filly (horse 2) from the same racetrack as
horse 1 presented approximately 24 hours after administration of the same compounded clenbuterol
product. Excitation, hyperhidrosis, muscle tremors and tachycardia were observed shortly after
administration. Treatments prior to admission included oral methocarbamol, milk of magnesia, valerian
root, buttermilk, acepromazine (0.06mg/kg [0.03mg/lb], IM, once), dexamethasone (0.04mg/kg
[0.02mg/lb], IV and IM, once each), flunixin meglumine (1.1mg/kg [0.5mg/lb], IV, once) and 8L crystalloid
intravenous fluids.
Abnormalities at presentation included tachycardia (112 bpm), hyperhidrosis, muscle
fasciculations and subcutaneous emphysema in the pectoral region. Electrocardiography confirmed
sinus tachycardia. Central venous pressure (CVP), measured via the right jugular vein, was increased at
22 cmH20.
Complete blood count was unremarkable. Serum biochemical analysis revealed hyperglycemia,
azotemia, hyperbilirubinemia, hypocalcemia, hyperphosphatemia, hypochloremia and increased creatine
kinase activity (Table 1). Serum clenbuterol concentration was confirmed to be 800 pg/ml by liquid
chromatography-electrospray-tandem mass spectrometry.
A rapid intravenous infusion of 10L crystalloid fluids, supplemented with calcium borogluconate
(4.6g/L), potassium chloride (20mEq/L), magnesium sulfate (1g/L) and dimethyl sulfoxide (13g/L), was
administered, followed by 7% hypertonic saline (500ml, IV, once). Propranolols (0.01mg/kg [0.05mg/lb],
IV, once), diluted in 150ml physiologic saline solution, was administered over 30 minutes. In response to
propranolol, heart rate decreased to 64 bpm, and CVP decreased to 15 cmH20. Muscle tremors did not
abate.
Butorphanol (0.03mg/kg [0.013mg/lb], IM, once), omeprazole (4.4mg/kg [2.0mg/lb], PO, q 24 h),
and insulin (0.22U/kg [0.1U/lb], IM, once) were administered, and molded frog support cushions were
applied on all four feet. Fluid therapy was maintained with Normosol-R at 1.5L/h, supplemented with
calcium borogluconate (20ml/L), potassium chloride (20mEq/L) and magnesium sulfate (0.5g/L). Ceftiofur
(2.2mg/kg [1.0mg/lb], IV, q 12 h) was also administered due to concerns about cellulitis in the pectoral
region.
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On day 2 of hospitalization, sinus tachycardia (64 bpm) and muscle fasciculations were still
present. Transient fever (101.4°F [38.5°C]) was observed. Reevaluation of the serum biochemistry panel
revealed resolution of hyperphosphatemia, hypocalcemia and hypochloremia, and improvement in the
degrees of hyperglycemia, azotemia, hyperbilirubinemia, and CK elevation. Prothrombin time (12.2 sec)
and partial thromboplastin time (43.9 sec) were mildly prolonged, but no clinical signs of coagulopathy
were observed. Insulin (0.12U/kg [0.05U/lb], SQ, once) was repeated, and supportive care was
continued.
By day 3 of hospitalization, blood glucose had normalized, azotemia was resolved, and heart rate
returned to normal (40-48 bpm). No signs of laminitis developed despite the presence of mild digital
pulses in the front feet. Intravenous fluid therapy was discontinued on the fourth day of hospitalization,
and the filly was eating, drinking, defecating, and urinating appropriately. Serum biochemical profile on
day 4 of hospitalization revealed residual elevations in total bilirubin and activities of CK, AST and ALP.
The filly was discharged after 5 days of hospitalization with no further medication required. All
clinical signs and clinicopathological abnormalities had resolved at the time of release, except for mildly
increased digital pulses.
3.1.3 Horse 3
A 533-kg (1173 lb), 3 year old Quarter Horse gelding (horse 3) in race training and housed at the
same barn as horses 1 and 2 was evaluated at the LSU-VTH & C for treatment of muscle tremors,
profuse sweating, and tachycardia following oral administration of a compounded clenbuterol product 24
hours prior to admission. Flunixin meglumine (1.1mg/kg [0.5mg/lb], IV, twice), acepromazine (0.06mg/kg
[0.03mg/lb], IM, once), dexamethasone (0.04mg/kg [0.02mg/lb], IV and IM, once each), lactated Ringer’s
solution (1L, IV, once) and oral methocarbamol were administered by the referring veterinarian. Valerian
root and milk of magnesia were given by the horse’s caretaker.
At presentation, sinus tachycardia (84 bpm), mild hypothermia (98.4°F [36.9°C]), profuse
sweating, prolonged capillary refill time (3 seconds), and whole-body muscle fasciculations were
detected. The quadriceps muscles were firm to the touch. Measurement of CVP was 7 cmH20 via the
right jugular vein. Initial fluid therapy consisted of rapid intravenous administration of both crystalloid and
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colloid fluids (Normosol-R, 10L, supplemented with calcium borogluconate at 4.6g/L, potassium chloride
at 20mEq/L and magnesium sulfate at 1mg/L; hetastarch 6%, 2L; 7% hypertonic saline, 500ml).
Hyperglycemia, azotemia, hyperbilirubinemia, hyperphosphatemia, hypochloremia, and increased
activities of CK, AST and ALP were present. A complete blood count was unremarkable. Urinalysis
revealed isothenuria, glucosuria, a large amount of blood, and trace proteinuria and ketonuria.
Following fluid resuscitation, CVP increased to 26 cmH20, and the horse became more agitated
and tachycardic. Propranolol (0.01mg/kg [0.005mg/lb]), diluted in 150ml physiologic saline solution, was
administered intravenously over 30 minutes. Heart rate, CVP and anxiety decreased following
propranolol administration, but muscle tremors and sweating continued. Insulin (0.22U/kg [0.1U/lb], IM,
once), butorphanol (0.028mg/kg [0.013mg/lb], IM, q 8 h), heparin (19U/kg [8U/lb], SQ, q 6 h) and
omeprazole (1.1mg/kg [0.5mg/lb], PO, q 24 h) were administered, and frog support pads were applied to
the front feet. Fluid therapy with balanced polyionic fluids was maintained at 1.5L/hr (Normosol-R,
supplemented with calcium borogluconate (4.6g/L), potassium chloride (20mEq/L), magnesium sulfate
(0.5g/L), and dimethyl sulfoxide (13g/L).
On day 2 of hospitalization, tachycardia (76 bpm) and muscle tremors were still present, and mild
pyrexia (101.5°F [38.6°C]) developed. Reevaluation of clinicopathologic parameters revealed resolution
of hyperphosphatemia. Hyperglycemia, azotemia, hypochloremia, and increased CK activity persisted,
and activities of AST and ALP had increased since admission. A left shift (1,000 band neutrophils/µl) was
evident on the complete blood count, despite a total leukocyte count (5,600/µl) and absolute neutrophil
count (3,200/µl) within the reference interval. Clotting times (PT, 12.6 sec; PTT, 44.9 sec) were mildly
prolonged. Propranolol administration was repeated as previously described and successfully decreased
the heart rate by about 10 bpm. Insulin (19U/kg [8U/lb], SQ, once) was also repeated, and all other
therapy was continued.
The horse subsequently developed mild bilateral forelimb lameness that progressed to signs of
acute laminitis by the end of day 2, despite application of ice to the front feet. Tripellenaminet (0.75mg/kg
[0.34mg/lb], IM, once), flunixin meglumineu (0.5mg/kg [0.22mg/lb], IV, once) and pentoxifyllinev (7mg/kg
[3.2mg/lb], diluted in 1L 0.9% saline, IV, q 8 h) were given. Reassessment of the serum biochemistry
panel revealed resolution of hyperglycemia and decreasing azotemia.
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The third day of hospitalization, the horse showed signs of acute laminitis in all 4 feet, and muscle
tremors persisted. No displacement of the distal phalanx was evident on lateral and dorsopalmar
radiographs of all 4 feet. Rectal temperature (101.5°F [38.6°C]), pulse (88 bpm), and respiratory rate (52
bpm) were all elevated. Perineural anesthesia of the digital nerves of all 4 limbs produced a temporary
but significant decrease in heart rate. Serum biochemical abnormalities were resolved, with the exception
of azotemia (BUN 27mg/dl, creatinine 2.7mg/dl) and elevated activities of AST (1060 U/L), ALP (959 U/L)
and CK (1550 U/L). Mild leukopenia (4,500/µl) and neutropenia (1,800/µl) developed, and a persistent
left shift (200 bands/µl) was present.
Phenylbutazone (4.4mg/kg [2mg/lb], IV, q 24 h) and butorphanol (0.056mg/kg [0.025mg/lb], IM,
once) were administered. Frog supports, lower limb support bandages and ice were applied to all 4
limbs. Under heavy sedation, the horse was placed in a sling. Muscle fasciculations ceased when the
horse was non-weight bearing. A constant rate infusion of ketaminew (0.4mg/kg/h [0.2mg/lb/h], IV) was
initiated while the horse was sedated and continued while slung. Crystalloid fluids and other medications
were continued. Feces became soft on day 3; di-trioctahedral smectitex was administered.
By the morning of day 4 of hospitalization, the patient was still tachycardic (80 bpm). Complete
blood count revealed mild neutropenia (1900/µl) with a degenerative left shift (1300/µl), lymphopenia
(800/µl), and monocytosis (1100/µl). Elevations in serum activities of AST (1179 U/L), ALP (1108 U/L)
and CK (1408 U/L), hypocalcemia (9.8mg/dl), hyperbilirubinemia (4.9mg/dl) and hypoproteinemia
(5.3g/dl) were detected. Over the next 12 hours, fecal consistency returned to normal, and smectite
treatment was discontinued, along with ice application and heparin. Fluid administration rate was
reduced to 1L/h, and the gelding was removed from the sling. Muscle fasciculations, tachycardia (84
bpm) and tachypnea (72 bpm) recurred after removal from the sling. Oral mucous membranes also
became congested, and a fever of 102.1°F (38.9°C) developed. Endoserum (1 L, IV at 0.5L/h) was
administered but did not alter vital parameters.
On the 5th day of hospitalization, the patient was febrile (102.4°F [39.1°C]), tachycardic (72 bpm)
and severely tachypneic (84 bpm), with red, injected mucous membranes and a capillary refill time of 3.5
seconds. The horse continued to exhibit signs of laminitis. Unilateral serosanguinous discharge was also
noted from the left nostril. Thoracic ultrasound findings were consistent with pleuropneumonia. Comet
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tail artifacts were diffusely distributed throughout the cranial lung fields bilaterally, and bilateral pulmonary
consolidation was evident cranioventrally. Bilateral, anechoic pleural effusion (≤1 cm) was present
cranioventrally, and pericardial effusion was also identified.
Clinicopathologic reevaluation revealed hyperbilirubinemia (6.8mg/dl), persistently elevated AST
(1128 U/L) and ALP (1421 U/L) activities, hypophosphatemia (2.1mg/dl), and hypoproteinemia (5.1g/dl).
Creatine kinase activity had decreased to nearly normal levels (363 U/L, reference 0-350 U/L).
Hyperfibrinogenemia (700mg/dl) and neutrophilic leukocytosis (16,500 WBC/µl, 11,200 neutrophils/µl)
with a left shift (3,600 bands/µl) were present. Humane euthanasia was performed at the owner’s
request. The horse was euthanized by barbiturate overdose.
3.2 Post-Mortem Findings
3.2.1 Horse 1
The muscles of the upper pelvic limbs contained multifocal to coalescing areas of abnormally
firm, pale pink to white discoloration bilaterally. Histologically, these muscles displayed multifocal to
coalescing necrosis of myocytes, affecting individual fibers as well as large muscle bundles. Skeletal
myocyte necrosis was characterized by hypereosinophilia, cytoplasmic vacuolization, loss of cellular
detail, swollen myofibers, and loss of cross-striations. Hypaxial muscles were diffusely swollen, soft, and
were mottled with dark red, patchy to coalescing areas of hemorrhage. Myocyte necrosis, characterized
by hypereosinophilia, fragmentation of muscle fibers, loss of cellular detail, loss of cross-striations, and
muscle fiber loss, was evident histologically (Figure 2). Frequent blood clots, defined by large areas of
hemorrhage containing fibrin and inflammatory cells, were also interspersed in the hypaxial muscles.
Although not grossly abnormal, the myocardium was necrotic on histologic examination.
Degenerate to necrotic cardiomyocytes occurred as scattered individual cells and in small clusters,
characterized by myofiber fragmentation, hypereosinophilia, cytoplasmic granularity, and occasional loss
of cross-striations (Figure 3). Multifocal interstitial edema and focal subendocardial hemorrhage were
present.
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Figure 2. Skeletal muscle from horse 1, hematoxylin & eosin. Cross-sectional (A, 600X) and longitudinal
(B, 100X) photomicrographs demonstrate extensive cellular injury via Zenker’s necrosis, contraction band
formation and myocyte fragmentation.

Figure 3. Cardiac muscle from horse 1, hematoxylin & eosin, 200X. A cluster of hypereosinophilic,
necrotic cardiac myocytes is noted in the center of this photomicrograph.
The bladder contained reddish-brown, cloudy urine. Mild to moderate renal tubular degeneration
and necrosis was present in the renal cortex, characterized by individual hypereosinophilic cells with loss
of nuclear detail, sloughed pyknotic cells within the tubular lumen, or the occasional presence of flattened
epithelial cells lining renal tubules. In the tubules of the cortex and medulla, accumulation of eosinophilic,
proteinaceous globules and red, granular casts was widespread. Together with the post-mortem
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confirmation of rhabdomyolysis, kidney lesions were consistent with acute renal failure due to pigment
nephropathy.
Moderate, diffuse, hepatic hemosiderosis, and pulmonary congestion and edema with severe
hemosiderosis were also present. Changes in the lungs, liver, and heart were compatible with acute
heart failure or acute cardiac insufficiency.
The samples of liver and kidney obtained post-mortem, approximately 48 hours post-clenbuterol
administration, as well as the serum sample drawn 24 hours post-administration, were analyzed for
clenbuterol residues by liquid chromatography-electrospray-tandem mass spectrometry. All samples
were positive for clenbuterol, with tissue concentrations being significantly higher than serum
concentration. Clenbuterol in serum 24 hours after ingestion was present at 5,450pg/ml. At 48 hours
after ingestion, clenbuterol was detected in liver at 376,890pg/ml and in kidney at 202,240pg/ml.
3.2.2 Horse 3
Skeletal muscle lesions in horse 3 were limited to the detection of diffuse, small, multifocal areas
of myocyte mineralization. The myocardium of the ventricular free walls and interventricular septum was
diffusely and asymmetrically discolored by pale tan streaking, with the left ventricular free wall being the
most severely affected. Approximately 40% of the heart exhibited tan discoloration grossly, and 25% of
sections examined microscopically exhibited cardiomyocyte necrosis or inflammatory changes.
Cardiomyocyte necrosis was characterized by loss of cross-striations, fragmentation, cellular
vacuolization, karyolysis, nuclear pyknosis, and sarcolemmal sheath collapse. Perivascular tissue and
areas of the myocardium surrounding Purkinje cells were expanded with granulomatous infiltrate and
either non-staining fluid or a basophilic, mucinous material. Approximately 200 ml of dark yellow fluid was
present in the pericardial sac. Aerobic bacterial culture of pericardial fluid was negative.
Subcapsular petechial hemorrhage was observed in the kidneys bilaterally. Non-specific
degenerate and necrotic lesions were identified in the renal tubules, along with evidence of tubular
epithelial repair. The bladder contained normal-appearing urine.
The cranioventral lung was sharply demarcated bilaterally by dark green consolidation,
encompassing about 20% of the lung parenchyma, and the remaining lung tissue was rubbery and
partially collapsed. Interlobular spaces in the consolidated area were expanded with edema and yellow,
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friable material consistent with fibrin, and the pleural surface was covered by a thin layer of similar brown,
friable material. The trachea and bronchii were filled with clear to white foam. Aerobic bacterial culture of
affected lung yielded a mixed population of Pseudomonas aeruginosa, Escherichia coli, Klebsiella spp.
and Proteus spp., consistent with aspiration pneumonia. Histologically, parenchymal necrosis, edema,
vascular necrosis and suppurative exudate were evident in the cranioventral lungs, and large numbers of
chain-forming cocci were present in necrotic foci. Neutrophilic infiltration was identified in the adventia
and mucosa of the trachea.
The liver was firm with an accentuated lobular pattern on gross examination. Mild vacuolization
of centrilobular hepatocytes, mild biliary hyperplasia and mild lymphocytic infiltration of the portal triads
were present.
The glandular portion of the stomach was thickened and hyperemic, and about half of the
affected area was covered with a fibrinous pseudomembrane that was colonized with coccobacilli. Mild
lymphocytic-plasmocytic inflammation was also present in the small intestine and large colon. Laminar
edema of the right fore and left rear feet was noted, consistent with laminitis.
The tissue samples and stomach contents obtained post-mortem, approximately 114 hours postclenbuterol administration, as well as the serum sample drawn 24 hours post-administration, were
analyzed for clenbuterol residues by liquid chromatography-electrospray-tandem mass spectrometry. All
samples were positive for clenbuterol. Serum clenbuterol concentration 24 hours post-ingestion was
1,050pg/ml. At 114 hours post-ingestion, clenbuterol was detected in liver at 6,790pg/ml, in kidney at
1,700pg/ml, in spleen at 1,550pg/ml, in brain at 1,080pg/ml, and in stomach contents at 1,150pg/ml.
3.3 Discussion
This report describes 3 cases of severe clenbuterol overdose in the horse. All horses exhibited
prolonged sinus tachycardia, muscle tremors, hyperhidrosis and anxiety. Similarly, reports of human
clenbuterol toxicity cite nervousness (91%), tachycardia (82-91%), distal tremors (75-88%), nausea
(74%), epigastralgias (68%), headaches and dizziness (36-42%), fever (36%), myalgias (20-22%),
hypertension (18%), and vomiting (18%) as the most common symptoms21,71. Horse 1 was admitted for a
history of colic signs, consistent with the high frequency of gastrointestinal upset in people. In our equine
patients, fever was an inconsistent finding. Horse 1 remained normothermic to hypothermic, possibly due
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to derangements in tissue perfusion. A single occurrence of fever was observed in horse 2 on the second
day of hospitalization and resolved spontaneously. The mild pyrexia observed in horse 3 was initially
attributed to clenbuterol effects, but its persistence may have been a sign of developing pneumonia.
The horses in this report were estimated to have received 10µg/kg (horses 2 and 3) or 100µg/kg
(horse 1) of the compounded clenbuterol. For treatment of respiratory disease in horses, clenbuterol is
approved for use at doses up to 3.2µg/kg. The serum concentration of clenbuterol detected in horse 1 at
admission was approximately 25 times higher than expected for a horse given clenbuterol within the
labeled dose range, based on a 24-hour withdrawal time25.
In the horse, side effects at or below 3.2µg/kg include mild tachycardia, anxiety, muscle tremors
and sweating, but signs are reported to subside within an hour of administration1. Conversely, symptoms
of clenbuterol toxicity in humans may last up to 6 days, and complications such as seizures and
supraventricular arrhythmias have been reported20,21,37,38,40, more closely resembling the cases described
in this report. Estimates of of oral clenbuterol doses resulting in human toxicosis range from 0.9µg/kg20 to
4.8mg/kg37. In one human case report, clinical signs persisted even after serum concentrations of
clenbuterol had decreased below detectable levels38. A similar phenomenon was present in our equine
patients.
Documentation of elevated tissue concentrations of clenbuterol in horses 1 and 3 may explain the
prolonged effects of clenbuterol (Table 2). Tissue clearance of clenbuterol is often prolonged relative to
serum clearance, and prolonged detection of clenbuterol is reported in the liver, kidney, eye fluids, lung,
heart and spleen of horses26. Due to its metabolism in the liver and excretion in the urine25, the liver and
kidney frequently contain concentrations of clenbuterol several times higher than that of serum20,21.
Table 2. Serum and selected tissue clenbuterol concentrations after clenbuterol overdose (ng/ml).
Horse 2
24 h
0.80

Horse 1
Time Post-Admin.
Serum
Liver
Kidney
Stomach Contents
Brain
Spleen

24 h
5.45

50 h
376.89
202.24

Horse 3
24 h
1.05

114 h
6.79
1.70
1.15
1.08
1.55
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Although the clinical signs of clenbuterol toxicity in horses closely parallel those in the human
literature, some of the clinicopathologic abnormalities appear to be unique. In people, hypokalemia,
hyperglycemia, hypomagnesemia and neutrophilic leukocytosis are frequently reported20,22,38.
Hypokalemia in all 3 horses was mild to absent. Serum magnesium concentrations were not measured in
our patients, but supplemental magnesium was provided based on human reports of hypomagnesemia
with clenbuterol overdose. Immature (band) neutrophils were detected in both non-surviving horses, but
only horse 1 exhibited absolute neutrophilia at admission.
The predominant alteration in the serum chemistry profile of all 3 horses was profound
hyperglycemia (Table 1). Hyperglycemia results from induction of glycogenolysis by hepatic β2
adrenoreceptors. This effect may be compounded by prolonged exposure of hepatic tissues to
clenbuterol; not only is the drug metabolized in the liver, but hepatic concentrations far exceed serum
levels for several days26. In contrast to the human literature, hyperglycemia in our equine patients did not
resolve spontaneously, and repeated administration of insulin was required to achieve normoglycemia.
Severe hyponatremia and hypochloremia are not reported in humans, but both abnormalities were
associated with non-survival in horses 1 and 3.
Adverse effects of clenbuterol may be broadly considered to arise from excessive adrenergic
stimulation. Clenbuterol is a moderately selective β2 adrenergic agonist, but at higher doses, all classes
of β-adrenoreceptors are activated. β2 adrenergic receptors are present in equine skeletal and cardiac
myocytes, hepatocytes, nervous tissue, respiratory smooth muscle, vascular smooth muscle, uterus, and
ileum1,12,27-30. In the vasculature, therapeutic doses of clenbuterol initially produce a decrease in blood
pressure, but this is counteracted within 2 minutes of administration by a reflex increase in heart rate and
pulmonary arterial pressure1. The higher doses of clenbuterol administered to our patients may have
contributed to the profound hypotension and alterations in perfusion seen in the 2 more severely affected
horses; possibly contributing to the development of laminitis in horse 3 and complicating treatment of
rhabdomyolysis in horse 1, respectively.
β1 adrenergic receptors in the myocardium may be stimulated directly by clenbuterol, or
secondarily by norepinephrine released from presynaptic sympathetic neurons responding to β2
activation28. In both skeletal and cardiac muscle, however, direct toxicity is mediated through pathways
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downstream of the β2 receptor. In rats, a single administration of clenbuterol at or above 10µg/kg
produces skeletal muscle necrosis, and doses at or above 100µg/kg induce cardiac necrosis8,10,12. In the
heart, this effect is most pronounced in the left ventricle. With repeated administration at or below
10µg/kg in rats, clenbuterol appears to induce muscle hypertrophy without adverse side effects; the
attenuation of myotoxic effects over time is thought to be related to downregulation of adrenoreceptors10.
Skeletal and cardiac muscle injury was demonstrated in both non-surviving horses. The dose of
clenbuterol administered to horse 3 was well below the dose which is reported to induce cardiac necrosis
in rats.
Clenbuterol also activates β3 (or “β-atypical”) receptors, which are purportedly responsible for the
lipolytic effects of clenbuterol, and which are relatively insensitive to blockade by the majority of βadrenergic antagonists, including propranolol1,27. β3 receptors have been identified in vascular smooth
muscle, adipocytes, liver, and the equine ileum. Activation of these receptors may contribute to the poor
response to β-blocker therapy in some patients.
A variety of targeted and symptomatic therapies have been used in clinical cases of human
clenbuterol ingestion, including β-blockers, anti-emetics, potassium chloride, and anti-convulsants such
as diazepam71. The β-blockers, including propranolol, are the most pharmacologically direct means of
counteracting β-adrenergic stimulation. Together with intravenous potassium chloride, they are
considered the treatment of choice for acute clenbuterol exposure in human medicine41,71. Repeated
administration of β-blockers may be required to control tachycardia and other manifestations of toxicosis
in people38,40. A similar phenomenon was observed in our equine patients and was attributed to
accumulation of clenbuterol in tissues or contributions from (refractory) β3 adrenoreceptor activity.
Although propranolol was effective at reducing heart rate in all cases, neither propranolol, any
sedative agent, nor any of the analgesics administered were effective at reducing anxiety and muscle
tremors. Provision of analgesia using a constant rate infusion of ketamine in the conscious horse has
been previously described72. Administration of ketamine using this protocol was attempted in horse 3
following the onset of laminitis. Although no adverse effects on mentation were noted, the desired
analgesic effects were likewise not appreciated in this case.
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Interestingly, all of our patients had received dexamethasone for symptomatic treatment prior to
admission. With chronic clenbuterol administration, tolerance develops as β2 receptors are
downregulated in lymphocytes, smooth muscle, and skeletal muscle, but receptor tachyphylaxis is
reversible by the administration of dexamethasone46. Although all horses presented with acute
clenbuterol overdose were accustomed to receiving clenbuterol, the protective effects afforded by
previous downregulation of β-adrenoreceptors could have been removed by dexamethasone-induced
upregulation shortly after the overdose.
In rats, pretreatment with selective β1 adrenergic antagonists, β2 adrenergic antagonists and
norepinephrine depletion with reserpine all attenuated cardiomyocyte injury by 91-100% in the face of
clenbuterol administration. However, treatment with β1 antagonists and reserpine did not reduce skeletal
myocyte necrosis12,28. Reserpine has been used to achieve long-term behavioral modification in horses.
Based on the aforementioned studies in rats, this drug may also have the potential to attenuate
cardiotoxicity in horses if given immediately after intoxication, or it may reduce the need for repeated βblocker administration to control tachycardia.
Enhancement of lean muscle mass and performance are the primary reasons for clenbuterol
abuse. However, several scientific investigations question the efficacy of clenbuterol as a performanceenhancing agent4-7,12,48. While clenbuterol has been repeatedly demonstrated to increase overall skeletal
and cardiac muscle mass3,10,33,34,44, its effects on tensile strength are variable3,34,48. Decreases in
exercise performance and an increased incidence of sudden cardiac failure have been described in rats4.
Studies investigating the effects of clenbuterol in both exercising and non-exercising horses
demonstrated repartitioning effects44,47, changes in myosin heavy chain composition45, cardiac function6,
and aerobic exercise performance5,7 using doses of clenbuterol within the recommended therapeutic
range for respiratory disorders. Demonstration of these same effects in rat models required doses up to
100 times higher than those used to treat respiratory disease in horses. These findings suggest that
horses may possess a different threshold for β-adrenergic agonist-mediated skeletal and cardiac muscle
response and injury than laboratory animal species. Closer investigation into the potential risks of
clenbuterol use among equine athletes not suffering from restrictive airway conditions is warranted.

29

In summary, a compounded formulation of clenbuterol was shown to be responsible for the
severe and prolonged clinical signs described in these 3 cases. A three- to 30-fold overdose was
suspected. The drug was present in the serum and tissues of these horses in excess of concentrations
expected from routine administration of the medication. Major features of toxicity included prolonged
sinus tachycardia, muscle tremors, hyperhidrosis and hyperglycemia. Complications were severe and
included rhabdomyolysis, renal failure, cardiotoxicity and laminitis. Propranolol was successful in
reducing heart rate in all horses, but it did not alleviate other signs of toxicity. The horse with the lowest
serum concentration of clenbuterol at admission survived. The high mortality rate of clenbuterol toxicosis
compared to human reports is attributable to the magnitude of the overdose in these horses.
3.4 Product Information

a

Robaxin®-V, Fort Dodge Animal Health, Fort Dodge, IA, USA

b

Normosol®-R, Abbott Animal Health, Abbott Park, IL, USA

c

Vetsulin®, Intervet/Schering-Plough Animal Health, USA

d

Heparin Sodium Injection (10,000U/ml), USP, Abraxis Pharmaceutical Products, Schaumburg, IL, USA

e

Torbugesic®, Fort Dodge Animal Health, Fort Dodge, IA, USA

f

Butaject 20%, Butler Animal Health Supply, Dublin, OH, USA

g

AnaSed® Injection, Lloyd Laboratories, Shenandoah, IA, USA

h

Endoserum®, IMMVAC, Inc., Columbia, MO, USA

i

6% Hetastarch, Baxter Healthcare Corporation, Deerfield, IL, USA

j

Naloxone Hydrochloride Injection (0.4mg/ml), USP, Hospira, Lake Forest, IL

k

PromAce® Injectable, Fort Dodge Animal Health, Fort Dodge, IA, USA

l

Dexamethasone Sodium Phosphate, 4mg/ml, USP, APP Pharmaceuticals, Schaumburg, IL, USA

m

Dormosedan®, Pfizer Animal Health, Exton, PA, USA

n

Guaifenesin (in 5% dextrose) for IV injection, 50mg/ml, Wedgewood Pharmacy, Swedesboro, NJ, USA

o

Diazepam Injection (5mg/ml), USP, Hospira, Lake Forest, IL, USA

p

Propranolol (1mg/ml), USP, Baxter Healthcare Corporation, Deerfield, IL, USA

q

Omeprazole Injection, 75mg/ml, Premier Pharmacy Labs, Inc., Weeki Wachee, FL, USA
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r

Naxcel®, Pfizer Animal Health, Exton, PA, USA

s

Duragesic® 100mcg/hr, Ortho-McNeil-Janssen Pharmaceuticals, Inc., Raritan, NJ, USA

t

Re-Covr® Injection, Fort Dodge Animal Health, Fort Dodge, IA, USA

u

FlunixiJect, Butler Animal Health Supply, Dublin, OH, USA

v

Pentoxifylline for IV injection, 4g, HDM Pharmacy, LLC, Lexington, KY, USA

w

Ketaset®, Fort Dodge Animal Health, Fort Dodge, IA, USA

x

BioSponge™, Platinum Performance, Buellton, CA, USA
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CHAPTER 4. EXPERIMENTAL INVESTIGATION OF THE EFFECTS OF CLENBUTEROL ON
SKELETAL AND CARDIAC MUSCLE
4.1 Introduction
Clenbuterol belongs to a class of bronchodilator agents known as β2 agonists. It is a moderately
selective β2-adrenoreceptor agonist that is licensed in the United States for the treatment of horses with
obstructive lower airway disease. Due to the multisystemic distribution of β2 receptors within the body,
clenbuterol also produces extra-therapeutic effects, both desirable and detrimental. Its augmentation of
lean muscle mass has made illegal use popular among livestock producers and human bodybuilders, and
its use is tightly regulated in performance horses, where the potential for abuse is also perceived to be
high. Cases of human clenbuterol toxicity have been reported with direct ingestion37,38,40 and secondary
to consumption of clenbuterol-contaminated meat products20-23. Side effects in humans range from
transient muscle tremors and gastrointestinal upset to severe, prolonged tachycardia with muscle
tremors, electrolyte derangements and supraventricular arrhythmias. Three cases of clenbuterol toxicity
in horses were reported in the previous chapter, in which clinical signs resembled those reported in
severely affected human beings.
In rats, clenbuterol reliably induces either necrosis or apoptosis in skeletal and cardiac muscle,
based on the dose administered8-12. Generally speaking, high doses induce necrosis, and lower doses
induce apoptosis. However, both equine and human cases of toxicity have been reported after ingestion
of clenbuterol doses well below those which cause signs of toxicity or measurable muscle damage in
murine specie. These studies suggest that horses and humans may be more sensitive to β-adrenergic
stimulation than rodents.
Previous studies have suggested that clenbuterol has a negative effect on aerobic athletic
performance7, but a specific mechanism for this effect has not been proven. Some previously reported
effects of clenbuterol, which may explain a reduction in aerobic capacity, include direct β2-mediated
myotoxicity resulting in apoptotic or necrotic cell death8-10,12,28, reduction of intracellular myocyte
phosphofructokinase activity42, and increased frequency of type IIX (fast-twitch) muscle fibers in
predominantly slow-twitch muscles42,45,49. The mechanism by which this change in predominant myosin
heavy chain type occurs is unknown. Based on documentation of skeletal muscle damage in the cases of
clenbuterol toxicity reported in the previous chapter, one may hypothesize that changes occur because of
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or in association with subclinical muscle damage in horses receiving “therapeutic” doses of clenbuterol.
No studies to date have examined the effects of exercise and clenbuterol on equine skeletal muscle
morphology or frequency of apoptosis in the horse, nor has alteration in echocardiographic function been
evaluated in horses receiving the dosing regimen employed in this study.
The purpose of the study described herein was to determine if evidence of skeletal and/or cardiac
muscle damage could be detected in horses receiving oral clenbuterol at doses commonly prescribed for
respiratory disease. Additionally, this study sought to quantify and compare echocardiographic
measurements, serum muscle enzyme activities and histologic characteristics of skeletal muscle in
horses receiving clenbuterol versus saline-treated control horses.
4.2 Materials and Methods
Twenty-three Thoroughbred mares and geldings were evaluated for inclusion in this study. All
animals were obtained from the research herd maintained by the Lousiana State University Equine Health
Studies Program and were returned to the herd at the conclusion of the study. This study conformed to
the University guidelines for animal use and was approved by the Louisiana State University Institutional
Animal Care and Use Committee.
4.2.1 Animal Selection and Treatment Group Assignment
Horses were between 3 and 10 years old at the time of evaluation and were free of obvious
lameness (less than grade 1/5 on all limbs, using the AAEP grading system). Animals were determined
to be healthy based on routine physical examination, complete blood count and serum biochemistry
panel.
An echocardiogram was performed during initial evaluation. Horses were excluded if significant
alterations in echocardiographic measurements of left ventricular size or function were detected69,70.
Thoracic auscultation during rebreathing and endoscopic examination of the upper airway and trachea
were performed. Horses were excluded if abnormal lung sounds were detected on auscultation or the
tracheal mucus score was greater than 1 on endoscopic examination18. Histopathology of
semimembranosus muscle biopsies was performed at an outside laboratorya, and horses were excluded
if significant lesions were reported.
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Twelve horses met all selection criteria and were randomly assigned to either the control group
(n=6) or the clenbuterol group (n=6).
4.2.2 Study Overview
Horses were housed in individual box stalls for 48 hours after initial evaluation for observation of
pain or other adverse events associated with the biopsy site. Pelleted feedb was provided twice daily, and
horses had constant access to water while stalled. A physical examination was performed once daily.
Horses were then turned out on pasture for at least 12 days before beginning the treatment protocol.
After a minimum of 14 days from initial evaluation, the treatment protocol was initiated. Horses
were housed in bedded box stalls during this time, and twice daily pelleted feedb and once daily grass hay
were provided. Water was available ad libitum. A physical examination was performed once daily, and
horses were monitored for signs of clenbuterol toxicity, including muscle fasciculation or stiffness, anxiety,
tachycardia and excessive sweating.
Horses were subjected to daily submaximal treadmill exercise during the treatment period.
Venous blood was collected from the jugular vein into sterile evacuated tubes containing no additivesc,
sterile evacuated tubes containing lithium heparind and sterile evacuated tubes containing K2EDTAe
during initial evaluation (pre-treatment, day 0) and on days 3, 6, 9 and 12 of treatment. During the
treatment period, samples were taken immediately prior to morning treatment administration, which was
approximately 12 hours after the previous evening’s treatment. Serum was separated within one hour of
collection and stored at -20°C until batched analyses were performed. Echocardiography was repeated
7 days after beginning treatment (day 8). Venous blood collection, echocardiography, and biopsy of the
semimembranosus muscle were also repeated 12 hours after completion of the treatment protocol (posttreatment, day 15).
4.2.3 Treadmill Exercise
Beginning on day 1 of the treatment period, horses were exercised on the Mustang 2000 highspeed treadmillf for a total of 15 minutes at a walk, trot, and fast canter. Treadmill exercise was
performed once daily on weekdays (5 days per week) for 14 days. Skin sutures were removed from the
biopsy site prior to beginning treadmill exercise. Speed for the walk (3.93 ± 0.31 mph) and trot (9.11 ±
0.60 mph) were determined subjectively based on each horse’s stride length and perceived level of
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exertion. Fast canter speed (19.66 ± 1.27 mph) was determined on the first day of exercise as the
maximum speed at which the horse could keep pace with the treadmill for 2 minutes. Exercise intensity
was gradually increased during the first week of the treatment period by increasing the time spent at a
canter from 2 minutes on the first day to 5 minutes by day 8.
4.2.4 Medication Administration
Horses in the clenbuterol group (n=6) received clenbuterol as Ventipulmin® syrup (72.5µg/ml)g by
mouth twice daily (8am and 8pm) for 14 days. The dose was incrementally increased during the
treatment period to minimize adverse side effects, according to the following schedule: 0.8µg/kg twice
daily for 3 days, then 1.6µg/kg twice daily for 3 days, then 2.4µg/kg twice daily for 3 days, then 3.2µg/kg
twice daily for 5 days. Animals in the control group (n=6) received saline by mouth twice daily for 14
days. The volumes of saline administered each day were equal to the volumes of clenbuterol that would
have been administered.
4.2.5 Determination of Serum Clenbuterol Concentration
Determination of serum clenbuterol concentrations was performed on thawed serum using gas
chromatography following extraction with sodium hydroxide, petroleum ether and methylboronic acid.
A standard curve using known concentrations of metoprololol from 0.01 – 5.00ng/ml was generated in
order to determine the limits of detection for this method. Thereafter, metoprololol was used as an
internal standard to create a standard curve (linear regression) for each batch of samples tested, using
known concentrations of 0.25ng/ml, 0.50ng/ml, 1.00ng/ml, 2.50ng/ml, 5.00ng/ml and 6.00ng/ml. The
minimum acceptable R2 value for the resulting linear regression equation was set at 0.990.
4.2.6 Evaluation of Skeletal Muscle Effects
4.2.6.1 Creatine Kinase and Aspartate Aminotransferase Activity
CK and AST assays were performed on thawed (lithium) heparinized plasma by the LSU Clinical
Pathology Laboratory using the Olympus AU36E analyzerh.
4.2.6.2 Muscle Biopsy
Horses were sedated intravenously with detomidine hydrochloridei and butorphanol tartratej for
biopsies. Local anesthesia with 2% lidocainek was also instilled subcutaneously over the biopsy site.
Pre-treatment biopsies were taken from the semimembranosus muscle approximately 5 cm below the
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tuber ischii on the right side. Post-treatment biopsies were taken from the same muscle group on the
contralateral side, 12 hours after the final treatment administration.
Briefly, a 1” (2.5cm) cube of muscle was surgically excised through a 2.5” (5cm) incision. The
skin and subcutaneous tissues were closed in 2 layers with a simple continuous pattern using 2-0 nylonl
and 3-0 polyglactin 910m, respectively. Horses were administered 2 grams of phenylbutazonen
intravenously following each biopsy for analgesia and to minimize local inflammatory response.
A portion of the pre-treatment biopsy was wrapped immediately in a saline-moistened gauze
sponge, placed in a water-tight container surrounded by ice packs, and analyzed histologically at an
outside reference laboratorya to rule out pre-existing myopathy. The remaining portions of the pretreatment biopsies, as well as all post-treatment biopsies, were fixed in zinc formalin and embedded in
paraffin. For each horse, 2 paraffin blocks were prepared at each sampling point. From each available
paraffin block, one 5µm-thick section was stained with hematoxylin and eosin, and 2 sequential 5µm-thick
sections were cut for immunohistochemical staining.
4.2.6.3 Histopathology
Muscle specimens stained with hematoxylin and eosin were examined at 400X magnification by a
single blinded investigator (DBP). Slide-mounted specimens were evaluated for evidence of muscle
damage using the scoring system outlined in Table 3.
Table 3. Scoring system for histologic evidence of muscle damage. Specimens were scored subjectively
based on the degree of frequency and severity for each criterion.
SCORE

CRITERIA
0

1

2

3

Central nuclei

absent

rare

mild

moderate

Contraction band necrosis

absent

rare

mild

moderate

Intracytoplasmic granules

absent

rare

mild

moderate

Myocyte atrophy

absent

rare

mild

moderate

Myocyte fragmentation

absent

present

Swollen myocytes

absent

rare

mild

moderate

Zenker’s necrosis

absent

rare

mild

moderate
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4.2.6.4 Immunohistochemistry
The first of the 2 sequential muscle sections was evaluated for apoptosis using a polyclonal rabbit
anti-caspase 3 antibodyo with an avidin-biotin peroxidase complex systemp. Briefly, sections were
deparaffinized and rehydrated routinely with xylene and graded ethanol. Endogenous peroxidase activity
was quenched by incubation in 100µl of 3% hydrogen peroxide for 10 minutes, followed by protein
blockade with 100µl goat serum for 30 minutes. Sections were incubated in 100µl of a 1:1500 dilution of
the primary anti-caspase-3 antibody for 30 minutes, followed by application of 100µl biotinylated antirabbit secondary antibody for 30 minutes, 100µl of avidin and biotinylated horseradish peroxidase
complex for 30 minutes, and then 100µl of Nova Red peroxidase enzyme substrateq for 8 minutes.
Specimens were rinsed in Tris buffer between each step. Lastly, counterstaining was performed with
hematoxylin (100µl for 5 minutes), and specimens were cleared and dehydrated prior to permanent
mounting.
The corresponding sequential muscle section from each block was used as a negative control by
substituting deionized water for the primary anti-caspase 3 antibody in the first step of the procedure.
Muscle sections from a case of clenbuterol toxicity reported in the previous chapter (horse 1) were also
processed in the same manner for comparison.
Sections of equine laminar tissue from a patient with laminitis were used as positive controls67.
Positive staining for caspase 3 was defined as bright red stain uptake in either the nucleus or cytoplasm
of myocytes. Normal nuclei and sarcoplasm appeared various shades of purple. Muscle sections were
examined for apoptosis by a single blinded investigator (JAT). The entire section was classified as either
positive or negative for apoptosis based on presence or absence of positive (red) cytoplasmic or
perinuclear staining. In addition, nuclear staining characteristics were recorded for 500 nuclei per
specimen, and the percentage of positively-staining nuclei was recorded.
4.2.7 Evaluation of Cardiac Muscle Effects
4.2.7.1 Cardiac Troponin I Activity
Samples of K2EDTA plasma for cardiac troponin I (cTnI) analysis were shipped overnight on dry
ice to the Clinical Pathology Laboratory at the University of Florida. Assays were performed on thawed
EDTA plasma on the Bio-Site Triage MeterPlus, using Bio-Site Cardiac Panel cartridgesr.
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4.2.7.2 Echocardiography
Echocardiograms were performed using a 3.5mHz cardiac probe with a depth of 30cm attached
to a portable ultrasound machines. Hair was clipped over the right axillary region, and ultrasound coupling
gel was applied to improve image quality. 2-D and M-mode analyses were performed in order to obtain
standard measurements of cardiac function and contractility, specifically end-systolic and end-diastolic
measurements of left ventricular internal diameter (LVIDs, LVIDd), interventricular septal thickness (IVSs,
IVSd) and left ventricular posterior wall thickness (LVPWs, LVPWd), fractional shortening (FS), ejection
fraction (EF), and diameters of the aortic root (AR) and pulmonary artery (PA). All echocardiograms were
performed with horses at rest.
4.2.8 Statistical Analysis
The response variables CK, AST, cTnI, IVSd, IVSs, LVIDd, LVIDs, LVPWd, LVPWs, EF, FS, AR
and PA were compared between treated horses and controls and across time periods using a MannWhitney U test and Friedman’s test for repeated nonparametric data, respectively. An adjusted level of
significance at p<0.01 was used to reduce type I error. These response variables were summarized as
median and range.
The presence of apoptosis in muscle biopsy specimens was compared using a Cochran-MantelHaenszel stratified analysis, and the level of significance was set at p<0.05. Percent apoptotic nuclei and
serum clenbuterol concentrations were summarized as mean ± standard deviation. All statistical
analyses were performed using statistical softwaret.
4.3 Results
4.3.1 Treatment Groups
Of 23 horses initially evaluated, 12 met the inclusion criteria. Of the 11 horses excluded, 1 was
excluded due to reduced fractional shortening, and 10 horses were excluded based on abnormal muscle
biopsy; 1 of these horses also had echocardiographic evidence of cardiac insufficiency. Horses in the
control group (n=6) ranged in age from 3 to 10 years and included 2 mares and 4 geldings. The
clenbuterol group (n=6) was comprised of 6 geldings between 4 to 7 years of age. There was no
significant difference in age distribution between control and clenbuterol horses.
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4.3.2 Effects on Skeletal Muscle
4.3.2.1 Creatine Kinase and Aspartate Aminotransferase Activities
Prior to treatment (day 0), the median activity of CK in control group horses was 226 U/L (range,
174 – 286 U/L). The median activity of AST in control group horses was 242 U/L (range, 164 – 316 U/L).
Among horses in the clenbuterol group on day 0, the median activities of CK and AST were 234 U/L
(range, 112 – 384 U/L) and 243 U/L (range, 166 – 268 U/L), respectively.
On day 3, median activity of CK in the control group was 179 U/L (range, 141 – 215 U/L), and
median activity of AST was 229 U/L (range, 167 – 289 U/L). In the clenbuterol group, median activity of
CK was 175 U/L (range, 115 – 268 U/L), and median activity of AST was 214 U/L (range, 173 – 313 U/L).
On day 6, CK activity above the reference interval was detected in 1 horse in the clenbuterol
group, but this value did not significantly alter the overall CK activity of this group as compared to the
control group. Median CK activity in the control group was 180 U/L (range, 141 – 215 U/L) versus 169
U/L (range, 106 – 860 U/L) in the clenbuterol group. Median AST activity in the control group was 228
U/L (range, 167 – 289 U/L), and median AST activity in the clenbuterol group was 202 U/L (range, 158 –
294 U/L).
Median activities of CK and AST on day 9 were 201 U/L (range, 127 – 319 U/L) and 238 U/L
(range, 183 – 314 U/L), respectively, for horses in the control group; and 239 U/L (range, 128 – 320 U/L)
and 198 U/L (range, 175 – 376 U/L), respectively, for horses in the clenbuterol group.
On day 12, median CK activity of the control group was 170 U/L (range, 123 – 320 U/L), and
median AST activity of the control group was 226 U/L (range, 179 – 288 U/L). For the clenbuterol group,
median CK activity was 150 U/L (range, 129 – 244 U/L), and median AST activity was 198 U/L (range,
176 – 343 U/L).
The medians of the post-treatment (day 15) activities of CK and AST were 154 U/L (range, 126 –
194 U/L) and 215 U/L (range, 172 – 261 U/L), respectively, for horses in the control group. For horses in
the clenbuterol group, median CK activity was 129 U/L (range, 123 – 156 U/L), and median AST activity
was 198 U/L (range, 171 – 333 U/L).
There was no significant difference in CK (Figure 4) or AST activities (Figure 5) between
clenbuterol-treated horses and controls or across time periods for either treated horses or controls.
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Figure 4. Scatter plot of CK activities (U/L). Values for clenbuterol-treated horses are denoted by the
blue boxes ( ), and values for saline-treated horses are identified by the purple diamonds ().
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Figure 5. Scatter plot of AST activities (U/L). Values for clenbuterol-treated horses are denoted by the
blue boxes ( ), and values for saline-treated horses are identified by the purple diamonds ().
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4.3.2.2 Pre-Treatment Muscle Biopsy Classification
Of the 22 samples sent to the University of Minnesota for histologic evaluation, 9 were classified
as normal muscle biopsies, 3 were suspicious for vitamin E deficiency, 4 were classified as having a nonspecific myopathy, 5 were diagnosed with polysaccharide storage myopathy (PSSM), and 1 sample
exhibited pathologic changes consistent with recurrent exertional rhabdomyolysis (RER).
4.3.2.3 Histopathology
Ten horses had both pre- and post-treatment muscle biopsies available for sectioning. Posttreatment biopsies were unavailable for 1 horse from each group. Table 4 details the histologic scores for
all biopsies examined. A trend towards a higher score for contraction band necrosis is apparent in the
post-treatment biopsy specimens of horses treated with clenbuterol, as compared with control horses.
Table 4. Histologic scoring of muscle biopsy sections. For most morphologic criteria, scores range from
0 (absent) to 3 (moderate). Myocyte fragmentation is scored as 0 (absent) or 1 (present).
HORSE
GROUP
Central nuclei
PRE
POST
Contraction bands
PRE
POST
Intracyt. granules
PRE
POST
Myocyte atrophy
PRE
POST
Myocyte fragment.
PRE
POST
Swollen myocytes
PRE
POST
Zenker’s necrosis
PRE
POST

1
CON

2
CLB

4
CLB

5
CLB

7
CON

8
CON

9
CLB

11
CON

18
CLB

21
CON

0
1

1
1

0
1

0
1

0
0

0
1

1
1

1
1

1
1

0
1

0
0

1
1

0
3

2
2

0
0

0
0

0
2

0
0

0
3

0
0

1
2

2
1

2
2

1
1

0
1

0
1

2
2

1
0

2
1

3
0

1
2

2
1

1
1

1
1

0
0

0
1

2
2

1
1

2
1

1
1

0
0

0
0

0
0

0
0

0
0

0
0

0
1

0
0

1
0

0
0

1
1

1
0

1
1

0
0

1
1

1
1

1
1

1
0

1
1

1
2

0
1

1
0

1
1

0
1

0
0

0
0

0
1

0
1

0
0

0
0

*CLB = clenbuterol group
*CON = control group
*PRE = pre-treatment (day 0)
*POST = post-treatment (day 15)
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4.3.2.4 Immunohistochemistry
Ten horses had both pre- and post-treatment muscle biopsies available for sectioning. Posttreatment biopsies were unavailable for 1 horse from each group. No pre-treatment biopsies were
classified as positive for cellular apoptosis. Three post-treatment sections from the control group and 2
post-treatment sections from the clenbuterol group displayed cytoplasmic staining (Figure 6A).
Statistically, there was no significant interaction of group or time on the presence of apoptosis.

A

B

Figure 6. Semimembranosus muscle, 600X. Post-treatment caspase 3 immunohistochemical assays.
The arrows denote positive Nova Red-staining apoptotic cells (A) and nuclei (B).
The mean percentage of caspase 3-positive nuclei in the pretreatment biopsies was 24.6 ± 7.56%
for the control group and 19.0 ± 7.91% for the clenbuterol group. Post-treatment, the mean percentage of
positively-staining nuclei for the control group was 18.7 ± 5.63%, versus 25.6 ± 7.85% for the clenbuterol
group. Figure 6B depicts a specimen with a high percentage of positively stained nuclei. The
observation of relatively frequent nuclear staining did not appear to change with exercise conditioning or
clenbuterol treatment, unlike the observation of rare cytoplasmic staining. Considering that nuclear
staining appeared to occur at a constant rate in all groups, and that caspase 3 is primarily a cytoplasmic
enzyme, nuclear staining was interpreted as artifact.
4.3.3 Effects on Cardiac Muscle
4.3.3.1 Cardiac Troponin I Activity
Activity of cTnI was elevated in 1 horse (5ng/ml) in the clenbuterol group on day 6. For this horse
at all other time points, and for all other horses at all time points, cTnI activity was less than 0.05ng/ml.
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There was no significant difference in cTnI between treated horses and controls or across time periods for
either treated horses or controls.
4.3.3.2 Echocardiography
There was no significant difference between treated horses and controls or across time periods
for either treated horses or controls in all variables examined (IVSd, IVSs, LVIDd, LVIDs, LVPWd,
LVPWs, EF, FS, AR and PA). Table 5 summarizes the measured echocardiographic variables.
Table 5. Median values of measured echocardiographic variables. CLB = clenbuterol group.
DAY 0

DAY 8

DAY 15

CONTROL

CLB

CONTROL

CLB

CONTROL

CLB

IVSd (cm)

3.18

2.99

3.20

3.02

2.99

2.89

IVSs (cm)

4.58

4.57

4.56

4.55

4.49

4.42

LVIDd (cm)

12.02

12.11

12.24

11.45

12.50

11.65

LVIDs (cm)

7.75

7.21

7.76

7.35

7.25

6.69

LVPWd (cm)

2.34

2.25

2.18

2.10

2.20

2.24

LVPWs (cm)

3.48

3.94

3.55

3.71

3.74

3.66

EF (%)

60.52

69.40

60.94

67.77

63.92

66.37

FS (%)

35.49

41.71

36.48

40.20

38.30

42.10

AR (cm)

7.36

6.97

7.24

7.37

7.50

7.45

PA (cm)

4.64

4.36

4.86

4.71

4.74

4.58

4.3.4 Serum Clenbuterol Concentrations
The limit of detection for clenbuterol using gas chromatography was 0.25ng/ml (250pg/ml).
Clenbuterol was not detectable in the serum of any horses prior to treatment (day = 0) or in the serum of
saline-treated controls at any time point. For horses treated with clenbuterol, mean serum concentration
of clenbuterol on day 3 was 635.2 ± 173.9 pg/ml. The morning of day 6, mean serum concentration was
1142.8 ± 292.1 pg/ml, and on day 9, mean serum clenbuterol levels were 1874.5 ± 526.4pg/ml. For days
12 and 15, mean serum clenbuterol concentrations were 2232.3 ± 717.7 pg/ml and 2819.0 ± 759.2 pg/ml,
respectively. Figure 7 depicts the increase in serum clenbuterol levels during the treatment period.
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Figure 7. Serum clenbuterol concentrations (ng/ml) increased in treated horses throughout the treatment
period. Dots represent mean concentrations, and error bars represent 1 standard deviation.
4.3.5 Adverse Events
Colic was the most frequently encountered adverse event, occurring in 3 horses. One horse in
the clenbuterol group developed a large colon impaction and colon displacement on day 7 of treatment,
necessitating early removal from the study. This horse was removed from final data analysis; therefore
complete data were only available for 5 horses in the clenbuterol group.
One horse in the clenbuterol group developed a large colon impaction during the last week of the
study, and one horse in the control group developed colic during the observation period after study
completion. Both cases resolved within 24 hours with administration of flunixin meglumine and oral fluids.
One horse in the control group developed diarrhea at the beginning of the study, which resolved within 48
hours after beginning treatment with di-trioctahedral smectiteu, bismuth subsalicylate and metronidazole.
One horse in the clenbuterol group experienced incisional dehiscence 7 days after pre-treatment biopsy,
but the site healed well by second-intention after daily lavage, and the horse was able to begin treadmill
exercise on schedule with no lameness.
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Tachycardia, muscle tremors or other signs of clenbuterol toxicity were not recorded for any
horse at any time point. Subjectively, horses in the clenbuterol group sweated more readily during
treadmill exercise, and their perspiration did not decrease with conditioning, as it did in the control horses.
Exercise tolerance was not specifically assessed, and all horses were able to complete the prescribed
exercise protocol at all times.
4.4 Discussion
No adverse effects were associated with clenbuterol administration in the present study. The
gradually increasing dose schedule used in this study, as recommended by the manufacturer, was
intended to reduce the incidence of adverse effects; “tolerance” was likely induced due to progressive
receptor down-regulation. Previous investigators reported that horses in their studies were unable to
tolerate doses of clenbuterol higher than 2.4µg/kg every 12 hours; the reduction in sensitivity associated
with receptor tachyphylaxis most likely accounts for the failure of this study to reproduce previously
reported deleterious effects of clenbuterol.
4.4.1 Effects on Skeletal Muscle
The current study failed to find any association of clenbuterol or exercise conditioning with the
selected indicators of skeletal muscle damage. The finding that CK did not increase with clenbuterol
administration, particularly at higher doses, was unexpected and inconsistent with data reported by the
manufacturer. However, publicly available information does not specify to what extent CK was reportedly
elevated, nor at what time point following clenbuterol administration that CK elevation occurred. In clinical
trials of human cardiac patients receiving clenbuterol at doses between 80 to 720µg/day, elevated CK
activities were reported in approximately 50% of subjects3,34. It is possible that a change may have been
detected with a different sampling time or a more frequent collection of samples. CK levels peak within 4
to 6 hours of muscle damage, but rapidly decline in the absence of further degeneration.
Blood samples were collected 15-20 hours post-exercise, when CK levels may have been
returning to normal after potential exercise-induced injury. However, elevations in AST activity would still
be expected under these circumstances. The sampling time in this study was chosen to correspond with
the time that clenbuterol induces maximal myocyte necrosis in rats8. Fillies in race training are reported
to have a higher prevalence of elevated CK and AST activity than colts73; the absence of females in the
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clenbuterol group may have further reduced the probability of detecting alterations in these parameters. It
is worth mentioning that in many of the studies which found negative effects of clenbuterol, the study
population was comprised exclusively of mares5,6,74.
The semimembranosus muscle was chosen for evaluation because this muscle group is the
optimal site to detect common equine myopathies on routine biopsy52. Unfortunately, this muscle is
normally composed of 70-75% glycolytic (type IIX) fibers75, which are not the primary fiber types affected
by clenbuterol in other species49, thereby limiting the probability of detecting an effect of clenbuterol. In
murine studies, a significant difference in response to clenbuterol has been reported between skeletal
muscles composed of predominantly fast-twitch fibers, those composed of mostly slow-twitch fibers, and
cardiac muscle2,8,10,42,43.
Based on the findings of Burniston et al 8-10,12, a high percentage of affected myocytes was not
expected; however, even a small percentage (i.e., 2-3%) of apoptotic cells may result in significant tissue
loss of up to 25% per day76. Most horses in this study lost weight during the treatment period. An initial
loss of total body mass has been previously reported in horses subjected to clenbuterol administration
plus exercise44; one explanation for this phenomenon is muscle tissue regression through apoptosis.
Histologic evidence of myotoxicity appears to be attenuated after 8 days in other species8, so the 14-day
treatment period used in this study may have further reduced the potential for detecting a significant
histologic difference between groups.
Overall, the small sample size was detrimental to the detection of differences between groups.
One barrier to obtaining a larger number of subjects was the unexpected high incidence of abnormal
muscle biopsy results during the screening process. Approximately half of the animals examined were
excluded from enrollment in the study based on abnormal muscle biopsies. Twelve out of 23 horses
screened had one or more histopathologic abnormalities, and 10 of these were severe enough to require
exclusion. Horses with pre-existing myopathy were excluded from this study, because elevations in
serum CK and AST activities are commonly documented in horses with conditions such as PSSM and
RER52, and inclusion of these horses in the study population could therefore confound interpretation of
any such occurrences as being attributable to clenbuterol administration. Previous studies examining the
effects of clenbuterol in horses5-7,44,45 did not consider this factor.
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Nevertheless, the high percentage (10/22, 45%) of horses affected with some form of
histologically apparent myopathy was an unexpected finding. The stated reason for donation of most
Thoroughbred horses to the research herd was poor racing performance; myopathy may be an underrecognized cause of poor performance in this population. In a retrospective analysis of causes of poor
performance, 10/348 (3%) of horses were identified as suffering from rhabdomyolysis, and 53/348 (15%)
of horses were diagnosed with subclinical myopathy based on abnormal post-exercise elevations in CK
activity53. The horses in the current study were not evaluated for myopathy using this method, so direct
comparison is difficult, but the prevalence of myopathy appears to be higher in our population than
previously reported. Further investigation would be needed to clarify the relationship between these
myopathies and poor performance, or response to clenbuterol in horses with and without myopathy. For
the horses examined in the present study, history of clenbuterol administration during their racing career
is unconfirmed but likely.
The effect of an inherent metabolic disorder of skeletal muscle on the potential for clenbuterolinduced myopathy is unknown, but one may speculate that its myotoxicity would be enhanced. For
example, RER is thought to result from a calcium channel defect. Although one report in equine skeletal
muscle did not find any change in calcium sensitivity in the fast-twitch muscle fibers of horses treated with
clenbuterol48, other studies in rats concluded that myocardial calcium sensitivity36 and sarcoplasmic
calcium content33 were increased with clenbuterol administration. Another study found that clenbuterol
interferes with the ability of epinephrine to inhibit insulin-stimulated glucose uptake by skeletal muscle77.
Whether this effect of clenbuterol increases the risk of rhabdomyolysis in horses already suffering from
disorders of glucose metabolism (such as PSSM or metabolic syndrome) has not been investigated.
4.4.2 Effects on Cardiac Muscle
This study failed to find an association of exercise conditioning or clenbuterol administration with
an increase in plasma cTnI or alterations in echocardiographic measurements at rest. Results of the
study presented here agree with part of a previous study6 that did not find an effect of clenbuterol on
resting echocardiographic parameters or plasma activity of cTnI, when given for 8 weeks at 2.4µg/kg.
However, Sleeper et. al. was able to demonstrate that significant changes in post-exercise
echocardiography do occur with clenbuterol treatment, regardless of exercise conditioning6. Due to
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limited data, this phenomenon was not observed in the present study. Only 1 horse in the clenbuterol
group and 1 horse in the control group underwent weekly post-exercise echocardiographic evaluation
during the treatment period, and a post-exercise echocardiogram was not performed in any horses during
the enrollment period (day 0). The data available from these 2 horses is therefore insufficient for any
significant statistical comparison.
One proposed mechanism for clenbuterol-associated cardiotoxicity is that of relative hypoxia, in
which the myocardial oxygen demand is increased beyond achievable levels by the positive inotropic and
chronotropic effects of clenbuterol7. Because treadmill speeds were arbitrarily assigned based on
perceived exertion, rather than a quantitative measure of exercise intensity such as heart rate or VO2, it is
possible that the horses in our study did not exercise sufficiently to induce hypoxic necrosis. However,
this explanation seems unlikely, as previous studies have shown exercise does not alter or potentiate
other effects of clenbuterol6,44,45.
Cardiac troponin I is used in clinical practice as a non-invasive indicator of myocardial damage.
Activity of cTnI increased outside of the reference range in only one horse at one time point, but changes
were not statistically significant when considered along with the rest of the treatment group. Since
echocardiography also failed to demonstrate significant changes in measured variables, we are unable to
evaluate the sensitivity of cardiac troponin I for measuring cardiac injury in this population.
Other markers of cardiac injury in humans include B-type naturietic peptide (BNP) and the cardiac
isoenzyme of CK. Although total CK activities for horses in this study were within the reference interval,
the relative activity of the cardiac isoenzyme versus the skeletal and brain isoenzymes was not
specifically evaluated, and it may have been abnormal or different between groups. In human medicine,
BNP is used as an indicator of left ventricular stretch in the evaluation of congestive heart failure, but it is
less reliable as a monitoring tool than cardiac troponin activity, as levels may be increased by a myriad of
non-cardiac causes such as renal disease, sepsis, acute respiratory distress syndrome or an increase in
circulating catecholamines63. BNP appears promising in the dog for differentiation of congestive heart
failure from non-cardiac causes of dyspnea78, but its clinical utility has not been validated in the horse.
Because the changes induced by clenbuterol appear to be clinically silent in the absence of
exercise, future investigation into the effects of clenbuterol on cardiac function should incorporate a
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standardized exercise test with documentation of heart rate and rhythm before, during and after exercise,
as well as consistent post-exercise echocardiography. Monitoring of exercise tolerance may also be
useful; methods were discussed in the previous section.
4.4.3 Serum Clenbuterol Concentration
Confirmation of serum clenbuterol concentrations in all treatment-group animals excludes the
possibility that the lack of effects seen were due to inadequate drug administration. Previous reports on
clenbuterol pharmacokinetics have not delineated the effects of gradually increasing doses on serum
clenbuterol concentration. Two reports examining oral administration of 1.6µg/kg clenbuterol twice daily
concluded that the 12 hour serum trough concentration in the adult horse was 508.1 ± 249.4 pg/ml25 and
648.0 ± 189.7 pg/ml26 after 2 and 7 days, respectively. The results obtained in our population on day 6
(1142.8 ± 292.1 pg/ml), following 2 days of oral clenbuterol administration at 1.6µg/kg, are higher than
previously reported data. The reason for this discrepancy is unclear.
The dose of clenbuterol was held constant (at 3.2µg/kg PO q 12 h) from day 10 to day 14;
therefore the increase in serum clenbuterol concentration from day 12 to day 15 was unexpected. It is
possible that concurrent tissue clearance may have contributed to the continued elevation in serum
concentration at the later sampling point.
4.5 Product Information

a

Neuromuscular Diagnostic Laboratory, University of Minnesota College of Veterinary Medicine, St. Paul,

MN, USA
b

Purina® Horse Chow® 200, Land O’ Lakes Purina Mills, Gray Summit, MO, USA

c

BD Vacutainer® Clot Tubes, Becton Dickinson, Franklin Lakes, NJ, USA

d

BD Vacutainer® Heparin Tubes, Becton Dickinson, Franklin Lakes, NJ, USA

e

BD Vacutainer® EDTA Tubes, Becton Dickinson, Franklin Lakes, NJ, USA

f

Kagra Corporation, Fahrwangen, Switzerland

g

Boehringer Ingelheim Vetmedica, Inc., St. Joseph, MO, USA

h

Olympus America Inc., Center Valley, PA, USA

i

Dormosedan®, Pfizer Animal Health, Exton, PA, USA
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j

Torbugesic®, Fort Dodge Animal Health, Fort Dodge, IA, USA

k

Lidoject 2%, Butler Animal Health Supply, Dublin, OH, USA

l

Ethilon™, Ethicon, Inc., Somerville, NJ, USA

m

Vicryl™, Ethicon, Inc., Somerville, NJ, USA
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Butaject 20%, Butler Animal Health Supply, Dublin, OH, USA

o

Affinity-Purified Rabbit Anti-Human/mouse Caspase 3 Active (AF835), R & D Systems, Minneapolis, MN,

USA
p

Vectastain® Elite® ABC Kit, Vector Laboratories, Burlingame, CA, USA

q

Vector® NovaRED™ Substrate Kit, Vector Laboratories, Burlingame, CA, USA

r

Bio-Site, Inc., San Diego, CA, USA

s

GE Logiq Book Pro, Sound Technologies, Inc., Carlsbad, CA, USA

t

SAS® Version 9.1.3, SAS Institute Inc., Cary, NC, USA.
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BioSponge™, Platinum Performance, Buellton, CA, USA
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CHAPTER 5. SUMMARY AND CONCLUSIONS
Oral clenbuterol administration at up to 3.2µg/kg twice daily did not produce measurable adverse
effects on equine skeletal or cardiac muscle. However, as mentioned earlier, the small sample size limits
the power of detection of any negative effects on skeletal or cardiac muscle. At supra-therapeutic doses,
manifestations of toxicity in horses mimic signs reported in humans and can produce life-threatening
complications. The β-adrenergic antagonist, propranolol, may be useful in symptomatic treatment of
clenbuterol overdose in horses, but repeated administration may be required.
Although other studies in horses have demonstrated negative effects of low- to moderate-doses
of clenbuterol on endurance and echocardiographic parameters, and produced measurable effects on
lean muscle mass and fat mass, those studies identified changes after a much longer treatment period.
Another study suggested that aerobic capacity was compromised 30 minutes after administration of a
single dose of clenbuterol, but clenbuterol was administered intravenously in that study. The route and
time course of administration of clenbuterol used in the current experimental study is different from all
prior reports. It is possible that the significant changes detectable after 8 weeks of clenbuterol
administration, or immediately after intravenous administration, may not occur after only 2 weeks of oral
medication. Additionally, because aerobic capacity and exercise tolerance were not specifically
assessed, this study neither confirms nor refutes previous data regarding the effects of clenbuterol on
aerobic capacity or endurance.
Prolonged use of clenbuterol, particularly in the absence of therapeutic need, has been
documented by previous researchers to have detrimental effects on many factors affecting athletic
performance. Although these effects were not demonstrated in the present study, further investigation is
needed to determine at what time point measurable changes occur in the skeletal and/or cardiac muscle,
and if changes, once present, are reversible after discontinuing clenbuterol. This information would
permit better recommendations to be made regarding the safety of prolonged and/or repeated clenbuterol
administration. Because bronchiolar β-receptors are down-regulated after 1-2 weeks of clenbuterol
administration, prolonged administration beyond this time results in decreased efficacy, unless the horse
receives concurrent corticosteroid therapy or the clenbuterol dose is increased. Alternatively, clenbuterol
may be given intermittently for symptomatic treatment, or repeated courses of treatment given after

51

respiratory β receptors have re-upregulated. As all of these practices are common in the performance
horse industry, precise knowledge of the nature and extent of potential clenbuterol-induced injury is
important to protect the welfare of the equine athlete. The cases of clenbuterol overdose reported herein
underscore the concept that this medication is not completely benign.
However, at the dose, frequency, route of administration and duration of clenbuterol treatment
used in the experimental study, negative effects on skeletal and cardiac muscle were not demonstrated.
The dosing regimen used in this study is consistent with current recommendations for the use of
clenbuterol in the treatment of IAD in young, athletic horses, assuming that symptoms resolve after a
single course of treatment. Therefore, the results of this study suggest that clenbuterol, when
administered orally for 2 weeks or less to horses with no pre-existing myopathy, does not induce skeletal
or cardiac muscle damage. This finding is important, given the high prevalence and potential economic
impact of IAD in performance horses. Further research is needed to assess the effects and potential for
long-term skeletal and cardiac muscle damage associated with treatment periods longer than 14 days,
and in horses with pre-existing myopathy.
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